Characterization of Extracellular Zinc-mediated Inhibition of Human HRVs by Bennett, Ashlee Nicole















Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Graduate 













































Ashlee Bennett  







Characterization of Extracellular Zinc-mediated Inhibition of Human Rhinoviruses 
Ashlee Bennett  
 
As the predominant etiological agent of the “common cold,” human rhinoviruses (HRVs) have a 
substantial economic impact and contribute to severe respiratory complications in immune 
compromised and asthmatic individuals. While zinc (Zn) ions have been previously shown to 
have an inhibitory effect upon HRVs, clinical trials using Zn products have produced conflicting 
results, and the lack of a known mechanism of Zn inhibition has stymied therapeutic 
development. Previous research on the potential anti-rhinoviral mechanism of Zn compounds 
focused upon intracellular processes. My research has demonstrated that extracellular exposure 
of both major and minor group HRVs to Zn chloride (ZnCl) and Zn gluconate (ZnG) is sufficient 
to profoundly decrease the infectivity of the viral population. The infectivity of other 
representatives of the picornavirus family is not decreased in the presence of Zn compounds, 
suggesting that Zn-mediated virus inhibition is HRV specific. Other metal cations similar to Zn 
have not demonstrated HRV inhibition. Zn-based inhibition of HRVs is independent of pH, is 
effected within minutes and is dampened at lower temperatures. Furthermore, whereas EDTA 
can chelate Zn to prevent inhibition of HRVs, it cannot reverse the Zn-based inhibition after it 
has occurred. In addition, infectious center plaque assay (ICPA) and competition assay data 
suggest that this mechanism is not related to the virus-cellular receptor interaction, and that Zn-
treated viral capsids are still able to interact with receptor binding sites. Moreover, cultivation 
and analysis of Zn-resistant HRV1A isolates suggests that genomic discrepancies in the VP1 
capsid protein play a role in the mechanism of Zn inhibition. 3 distinct point mutations that 
conferred amino acid substitutions were found in multiple Zn-resistant isolates. Located in the 
exterior B-C loop and the interior viral-genome neighboring region of VP1, 2 out of the 3 
mutations resulted in a dramatic amino-acid polarity change which likely has the chemical 
consequence of effectively repelling 2+ cations such as Zn. Furthermore, northern blot analysis 
reveals that Zn-treated HRVs exhibit an increased susceptibility to genomic RNA degradation, a 
phenomena that may be facilitated by a Zn-mediated cleavage of viral RNA within the viral 
capsid. Zn complexed to cheLating compounds Hinokital (HK), Pyrithione (PT) and Pyrrolidine 
Dithiocarbamate (PDTC) also demonstrated extracellular HRV inhibition, with the sequence and 
ratio of exposure, or precipitate formation, modulating the outcome. It is not clear if these 
compounds augment the antiviral mechanism of Zn alone, or initiate a distinct antiviral 
mechanism unrelated to that performed by Zn in isolation. Based upon the data presented here, 
Zn mediated inhibition of HRVs can occur in a cell-independent, extracellular manner to degrade 
viral RNA and thereby abrogate viral infectivity. This mechanism may provide novel insight into 
further therapeutic development of these compounds or template the design of future small 
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Picornavirus overview & taxonomy  
 
 As obligate intracellular parasites, viruses require the faculties of a living host to 
replicate. While their range of dependencies on the living host vary, all viruses fundamentally 
lack the full complement of necessary enzymes for translation, the creation of an amino acid 
polypeptide from an mRNA transcript. Outside of a permissive host which possesses the 
metabolic utilities needed for viral replication, viruses essentially exist as inert chemical 
structures composed of genomic material surrounded by a proteinaceous shell, and in some 
species, a host-derived membrane. Their extreme dependency upon host organisms, minimal 
structure, and uniquely “pseudo-living” nature, has necessitated a divergent classification 
system, pared down from that seen with living organisms throughout biology. In addition to the 
Baltimore Scheme (Diagram 1.1) used to classify viruses based upon the nature of their genome 
and enzymatic requirements to generate mRNA, virus species are taxonomically delineated by 








Diagram 1.1 The Baltimore Scheme  
The steps necessary to obtain mRNA that can be interpreted by the host cell translation 




 The Picornavirus family, of the order Picornavirales, currently contains 18 different 
genera, all characterized as having a genome consisting of single-stranded RNA of positive 
polarity, allowing immediate recognition by host cell ribosomes, as well as sharing other 
structural and replicative similarities (2). Currently, preliminary guidelines for membership into 
the Picornaviridae family necessitates the identification of 3 key characteristics: (i) functionally 
homologous 2A, 2B and 3A polypeptides, and leader polypeptides; (ii) a structurally similar 
Internal Ribosome Entry Site (IRES) ; and (iii) the P1 and P2 genomic regions sharing greater 
than 40% identity, and the P3 region sharing at least 50% or greater identity (3). The importance 
and details of the aforementioned structures will be discussed in a following section. 
 Due to their rapid evolution, picornaviral species posses a great deal of genetic 
variability, leading them to be often described as “quasi-species”(4).  These quasi-species are 
defined as a polythetic class of similar strains that share a limited range of hosts, significant 
similarities in their replication cycle, and genetic compatibility (5). Genetic compatibility is 
defined as being able to undergo homologous recombination and having virtually identical 
genome maps. These characteristics do not preclude the possibility that picornaviral species may 
vary significantly in gene sequence, host range, and antigenicity. However, species which fit the 
aforementioned criteria are typically found to possess amino acid sequence identity of 70% or 
greater (4). Despite their similar structure, picornaviruses can cause a range of pathologies that 
vary in viral tropism and clinical severity (6). 
 
General Genomic Structure of Picornaviruses 
 
 Consisting of an individual, unimolecular single-stranded unit of RNA of positive 
polarity, picornaviral protein synthesis can be initiated immediately upon release into the host 
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cell cytoplasm, with the viral genome capable of acting in a manner analogous to mRNA (7). 
Directed by an Internal Ribosome Entry Site (IRES), picornaviral translation is cap-independent, 
a feature which facilitates viral exploitation of the host cell’s protein machinery (8). While a 
variety of post-translational viral protease activities unique to each genus lend diversity to the 
end product, the picornaviral genome is recognized for its highly-conserved, economical 
structure (4). Variations characteristic of each genus and species are primarily found within a 
limited region of the genomic blueprint, lending a plethora of genetic and phenotypic variation to 
a wide population of viruses, while maintaining their distinct genealogical identity. Averaging 
just 7 - 8 kb in length, the compact picornaviral genome contains a single Open Reading Frame 
(ORF) which effectively occupies 85-90% of the available coding region of the RNA (9). An 
indispensable 40-80 bp 3’ poly-A tail, whose length varies by viral species, is genetically 
encoded and extended during genome production (10). The 50-500 bp 5’ terminal region of the 
genome is believed to be unique to each species, and sports a small virus-encoded protein, VPg, 
linked to the 5’ most nucleotide which is always a “UU” sequence (11).  This species-specific 
region takes on a cloverleaf, or unbranched terminal stem structure, which in combination with 
the VPg protein, is believed to facilitate the priming of minus-strand RNA synthesis for the 
production of progeny virus genomes (12). The polyprotein open reading frame of 
picornaviruses consists of genes encoding viral capsid proteins, followed by genes which encode 
non-structural viral proteins necessary for genome replication, including the VPg protein (13). 
After translation initiation facilitated by the IRES, multiple self-cleavage events produce the 
distinct polypeptides which form viral proteins from this single open reading frame (14).    
 While significant variation is described among phylogenetic subtypes, the picornaviral 
genome is principally composed of a sequential cascade of structural and enzymatic proteins, 
 
 5 
flanked by 5’ and 3’ untranslated regions, and characterized by a series of self-cleavage events 
carried out by embedded proteinase domains that catalyze the production of functional viral 
proteins (15). 
 
 The 5’UTR of picornaviruses   
 
  Covalently attached to a 5’ terminal uridine of viral RNA by a ubiquitously conserved 
tyrosine residue, the picornaviral VPg protein is immediately followed by a terminal secondary 
structural element that predominately consists of low free-energy, unbranched-stems or 
cloverleaf structures (16). Variable in length and sequence, these 5’ terminal domain structures 
have been documented to bind multiple cellular and viral proteins to facilitate interaction 
between the 5’ and 3’ ends of viral RNA which is vital for the template-switching and negative 
strand synthesis steps of genome replication (2). In HRVs, this cloverleaf structure and 
downstream pyrimidine-rich tract are universally found to be vital for the conversion of viral 
RNA from a translation to replication template, despite the observation that the downstream 
pyrimidine tract varies dramatically, even among isolates of the same serotype (17). Immediately 
upstream of the polyprotein Open Reading Frame (ORF), one of 4 characteristic Internal 
Ribosome Entry Site (IRES) structures can be found which are responsible for the cap-
independent translation of picornaviral proteins (18). Utilizing a highly-conserved type 1 IRES 
structure, HRV protein translation is initiated after IRES-mediated binding of the 40s ribosomal 
subunit, and facilitates scanning to the proper ORF AUG codon, a process which subverts 
canonical cellular translation initiation and facilitates the preferential production of viral proteins 
(9). Highly variable among all picornaviruses, an additional spacer sequence ranging from 18-40 
bps is found 3’ of the IRES in HRVs, and forms a stem structure whose AUG start codon 
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arrangement is believed to be responsible for the “bait and switch” strategy of competitive 
ribosomal initiation that has been postulated (5). Furthermore, extreme variability documented in 
this isolate-unique, 5’ region suggests that it may play a role in evasion of host recognition, and 
avoidance of innate immunity processes (4). 
 
The ORF of picornaviruses 
 
 The single ORF of picornaviruses begins with the genetic encryption of the viral capsid 
proteins. The 5’ region of the ORF contains the genes for the 4 principal viral capsid proteins, 
VP4, VP2, VP3 and VP1, whose numeric designation is representative of their discovery, rather 
than their position within the genome, or size and structural importance (19). The smallest and 
characteristically interior capsid protein, VP4, is the first to be translated and is not found in all 
picornaviruses (4). VP4 is followed by VP2, VP3 and VP1, whose trimeric interaction forms the 
symmetrical repeating pattern and exterior surface area of the viral capsid (4). However in a 
process unique to different viral species, proteolytic cleavage of longer polypeptide precursors 
yields these individual protein products at different stages of viral translation. The first co-
translational proteolytic cleavage event in the picornaviral replication cycle separates the viral 
capsid protein polypeptide, “P1” from the growing amino acid chain (4). Following synthesis of 
the downstream viral 3C protease which catalyzes further cleavages, P1 yields VP1 and VP3, 
and also generates a precursor, VP0, which contains proteins VP4 and VP2 (20). Cleavage of 
VP0 to yield VP4 & VP2 is the final stage in polyprotein cleavage and is observed only in those 




Universal picornavirus structure and proteins  
 
 Averaging at just 30 nm in diameter, all picornaviruses share an approximately spherical 
appearance that is the result of icosahedral symmetry achieved by repeating units of just 4 
distinct viral capsid proteins (21). This metastable structure is described as having a pseudo-
triangulation number of 3, due to the chemical inequivalence of capsid proteins creating quasi-
equivalent interactions which distort what is theoretically a mathematically T-1 icosahedron (22). 
Consequently, each of the 60 triangle-like structures which compose the capsid can be divided 
into 3 smaller triangles, each with a smaller triangle being representative of a single polypeptide 
chain that is derived from one of the three major structural proteins (23). The largest of these 
structural proteins, VP1, is located around the five-fold axis of symmetry while VP2 and VP3 
alternately flank the two and three fold axes. VP4 remains within the interior of the capsid and 
may play a stabilizing role in capsid structure, or viral genomic RNA encapsidation (24). While 
picornaviruses share general topographic similarities, unique structures on the capsid surface 
such as protruding loops, canyons, pores and hydrophobic pockets lend huge variation in 
receptor affinity across the picornavirus family. These structural entities dictate the method of 
interaction with the cellular receptor the virion will used to gain entry, as well as playing a role 
in antigenic determination. Furthermore, these structural differences are believed to be 
responsible for the great degree of variation in physicochemical properties like buoyant density 
and pH lability observed from species to species (25).   
 The metastability necessary to allow extracellular stability and transmission from host to 
host, as well as disassembly to allow for replication, necessitates a set of carefully orchestrated 
structural changes as the virion attaches and enters the cell. While nuances exist from species to 
species, two primary approaches of receptor interaction are prevalent among picornaviruses. One 
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mechanism leads to the formation of a reshaped capsid by a quasi-mechanical interaction with 
the receptor that is believed to commit the virion to subsequent un-coating. Another approach 
involves a more straight forward surface-oriented attachment to the receptor which does not alter 
overall capsid structure (26). While research on the precise cellular entry mechanisms for 
different picornaviruses is on-going, it is generally accepted that receptor-mediated-endocytosis, 
wherein the virion is exposed to a low pH environment, is essential to ultimately deliver 
infectious RNA into the host-cell cytoplasm (27) . 
 The variety and minutiae of proteins and catalytic activity necessary to execute a 
picornavirus infectious cycle is highly variegated from species to species. However, there exists 
a central line-up whose presence and activity are conserved across the picornavirus family. In 
addition to the 4 canonical viral capsid proteins, proteins 2B, 2C, 3A, 3B, 3C and 3CD are 
universally found to play an integral role in the infectious cycle of all picornaviruses (4).  
 Protein 2B and its precursor 2BC are involved in the construction of membranous 
vesicles on which viral RNA replication is localized. Furthermore, an NH2 terminal amphiphatic 
helix seen in the 2B proteins of some species is thought to impede golgi trafficking and lower 
Ca2+ levels, thereby hindering apoptosis of the infected cell (28).  
 The picornaviral 2C protein is also implicated in the construction of membranous vesicles 
for RNA replication, however, its exact mechanistic role is unclear. While some studies have 
observed ATPase and RNA-binding abilities, a lack of structural data has left even its potential 
oligomerization in doubt (29). 
 Varying widely in length from species to species, the picornaviral protein 3A, and its 
precursor 3AB, have been shown to play a role in virulence and host range, in addition to a 
probable role as a co-factor during RNA replication in some species (30). Interception of protein 
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traffic between the cellular endoplasmic reticulum and golgi apparatus has also been reported for 
some enterovirus species (4).   
 Noted for it’s small size and hydrophobic patches, protein 3B -VPg is found covalently 
attached to the 5’ end of picornaviral RNA. While the structure has been determined for the VPg 
of poliovirus, the precise purpose for multiple copies of this protein found in some 
picornaviruses is unknown (4). Connected to the 5’ terminus of the viral genome via a 
phosphodiester bond with the hydroxyl of a tyrosine residue, these proteins play a priming role 
during the virus replication cycle and can be found within the viral capsid after having been 
encapsidated along with the viral genome during assembly (31).   
 Coined the “workhorses of the proteolytic cascade” protein 3C is responsible for the vast 
majority of secondary proteolytic cleavage steps in the picronaviral polyprotein processing 
necessary to create discrete viral proteins. After initial monomolecular cleavage which separates 
the P2/P3 junction, this cis-reactive enzyme catalyzes numerous polyprotein cleavage events as 
well as being postulated to play a role in inhibition of a variety of host cell processes, such as 
transcription, cap-dependent translation and cytoskeleton remodeling (32). 
 In many picornaviruses the 3CD precursor protein is also believed to be an active 
proteinase, acting on both the P1 and P3 cleavage sites (68). In addition, important regulatory 
functions have been observed such as binding to the 5’ cloverleaf structure of viral RNA and 
CRE RNA binding that is believed to help template the minus strand synthesis necessary for 
genome production. The solved structure of this protein from poliovirus bolsters its proposed 
RNA -binding ability (33). 
 Acting as the RNA-dependent - RNA polymerase, protein 3D and its derivatives are 
indispensable for picornaviral genome replication (33). This 460-470 amino acid protein plays a 
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paramount role in the replication complexes that facilitate the production of both plus strand and 
minus strand genomic RNA (34).  
 Additional proteins, such as the Leader (L) protein and the 2A protease, are unique to 
specific genera in the picornavirus family (35). The precise and perhaps varied functions of these 
proteins differ from species to species, with preliminary research indicating a thematic role in 
restriction of host cell factors that would be a disadvantage to viral occupation of the translation 
machinery. In particular, the Enterovirus 2A protease interaction with the cellular translation 
factor eIF-4G, is believed to give advantage to the IRES-dependent translation of viral proteins 
during infection (35).  
 
Picornavirus cell entry 
 
Without a host derived lipid envelope, picornaviruses cannot gain entry by fusion with 
the cellular plasma membrane. Consequently, qualities intrinsic to their capsid structure must 
provide a mechanism for translocation of nucleoprotein complexes into the cell. Unfortunately, 
several factors have stymied research progress into the precise mechanism of entry for most 
picornaviral species, such as the typically high particle to PFU ratio, general complexity and 
dearth of knowledge of endocytic pathways, and the potential for utilization of multiple routes of 
entry. One of the only firmly established facts regarding cell entry is that it seems to vary from 
genus to genus and even species to species, with even structural characteristics of the capsid 
often unable to accurately predict the route of entry. The majority of picornaviruses are believed 
to use some form of the clathrin-mediated endocytic pathway, but it is known that many 




Picornavirus translation  
 
 With an RNA genome that can serve as the equivalent of mRNA due to its positive 
polarity, production of viral proteins can occur immediately upon genome release into the 
cytosol. Furthermore, with an IRES, this translation is not dependent upon availability and 
assemblage of a multitude of initiation factors to get started. This ease of translation initiation, in 
combination with proteins that directly inhibit 5’ cap assembly, rapidly leads to viral translation 
dominating host cell resources (37). Exact IRES topography varies from species to species, but 
picornaviruses can be divided into four principle groups based upon general IRES structure and 
the cellular factors required to initiate translation. Characteristic of Enteroviruses and 
Cardioviruses, respectively, type I and type II IRESes require just 4 cellular initiation factors in 
addition to the 40s ribosomal subunit and ATP to initiate translation (38). Type IV IRESes, seen 
in hepatitis C virus and porcine teschovirus, are distinguished for their independence from eIF4G 
to function (4). Type III IRESes have not been extensively characterized and their initiation 
requirements are unknown. In addition, IRESes often require a number of specific RNA binding 
proteins known as IRES Trans-Activating Factors (ITAFs ) which may provide a stabilizing or 
ribosomal requirement role to optimize translation (39). Comprehensive characterization of these 
factors for each viral species is on going. In addition to the IRES and its associating factors, 
research supports the possibility that interaction between the 5’ and 3’ ends of the viral RNA 
genome may play a role in initiating gene expression, modulating gene expression, or both (4). 
Ribosomal identification of the inaugural AUG codon has been postulated to possibly require 
both ribosomal scanning and melting of RNA structures for different picornaviral species (40). 
However, the notable conservation of a polypyrimidine tract downstream of the IRES, but 
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located a precise distance upstream of the initiating AUG codon, implicates this motif as playing 
an important role in AUG selection (41). 
 After successful initiation, translation of the viral RNA genome’s single ORF occurs in 
conjunction with a series of characteristic cleavage events. While the mechanism varies among 
picornaviruses, the first primary cleavage event occurs co-translationally, separating the viral 
capsid polypeptides (P1) from downstream replication polypeptides (P2). A second primary 
cleavage event, more universal in mechanism among picornaviruses, is the intramolecular, cis-
cleavage between the 2C and 3A regions mediated by an iteration of the 3C proteinase whose 
degree of maturation necessary to carry-out the catalytic event varies by species (42). Following 
these two primary cleavage events, a series of secondary cleavage events mediated by the 3C or 
3CD protease produce precursors of the capsid and replication proteins (33). Additional 
secondary cleavage events are necessary in some picornaviruses, including the processing of the 
C terminus of an L protein, and alteration of the C-terminal 2A region (43). A final maturation 
cleavage during the final stages of virion production separates the VP4 and VP2 polypeptides 
concomitantly as RNA is inserted into the developing capsid structure (44). 
 
Picornavirus RNA genome replication  
 
 Most, if not all, non-structural proteins found in the P2 and P3 regions of the picornaviral 
genome play some role in RNA replication. The members of the P3 region play a more direct 
role in RNA synthesis, while many of the proteins of the P2 region have been shown to play a 
more peripheral, but nonetheless important role in the production of viral RNA by catalyzing 
structural rearrangements on the membranes where RNA replication is localized (28). Coding the 
viral capsid proteins, the P1 region of the picornavirus genome does not play a role in RNA 
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replication aside from the potential role of CRE elements within the P1 region which may 
interact with the VPg protein and assist in its priming functionality (45).  
 With a genome that can also serve as a template for translation, a picornaviral infectious 
cycle necessitates a mechanism to alternate the role of viral RNA between these two utilities so 
that viral proteins and progeny genomes can be produced in appropriate quantities (Diagram 
1.2). This process requires the rearrangement of host membranes to form supramolecular 
structures to act as a scaffold for RNA replication and capsid assembly, in addition to certain 
cellular and viral protein entities (1). In the immediate aftermath of infection, production of a 
sufficient quantity of viral capsid proteins, and proteins required for RNA synthesis, necessitates 
the predomination of viral RNA serving as a translation template. However, a mechanism must 
be in place to catalyze the shift from translation to RNA replication for a sufficient number of 
viral genomes to be produced for progeny virions, and it has been demonstrated that viral RNA 
cannot serve as a translation and genomic template simultaneously (37). It is believed that a 
negative-feedback loop predicated upon the accumulation of one or more viral proteins produced 
during translation must be responsible for this transition. However, the proteins or protein 
precursors which assume this responsibility is still debated. The most characterized mechanism 
involves cleavage of the cellular protein PCBP2, by viral protein 3C, or its precursor 3CD, which 
effectively inhibits or disfavors its involvement in translation, but does not preclude its ability to 
play a role in RNA replication. Additional research has also implicated a role for the host 
polypyrimidine tract-binding protein (PTB), which cannot continue to stimulate IRES-mediated 









Diagram 1.2 Picornavirus replication strategy  
With a positive-sense, single-stranded RNA genome, picornavirus genomes can act as mRNA 
when they first enter the cell cytoplasm and be translated by host cell machinery to make viral 
proteins, some of which are necessary to execute RNA genome production. A negative-sense 
full-length, single-stranded RNA is made to template the synthesis of more positive stranded 
RNA genomes for progeny virions. 
 
 Picornaviral RNA replication occurs on a vesicular, two-dimensional cytosolic-facing 
membrane surfaces (28). Only the membrane binding abilities of 2B, 2C and 3A that form the 
foundation of these replication “factories” have been extensively characterized. However, all of 
the proteins known to be involved in RNA synthesis can be found localized to the surface of 
these vesicles averaging 300 to 400 nm in diameter. Localization of viral RNA replication to 
these vesicles is thought to facilitate viral protein concentration dependent assembly of capsids, 
as well as well as sequestering of the viral RNA replication machinery from cellular mRNAs that 
it might otherwise copy (4). While numerous tethering and rearranging functionalities have 
purportedly been observed in various viral proteins in some picornaviral species, the presence of 
viral protein precursor 3AB alone has been shown to be sufficient to recruit the viral 3D 
polymerase to the replication sites on these vesicular membranes (46). For all picornaviruses, it 
is universally accepted that the viral VPg protein plays a central role as a primer for both 
negative and positive RNA strand synthesis. However, in many picornaviral species, the cis-
acting replication elements (CREs) located within the P1 region of the viral genome have also 
been reported to provide a priming functionality by acting as template for the advantageous 
uridylylation of VPg (30). Both the 5’ non coding region and the 3’ noncoding region of the viral 
genome have also been shown to play a role in the promotion of RNA synthesis, most likely 
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through the formation of secondary stem-loop and cloverleaf structures that might stabilize the 
picornaviral replisome. Furthermore, multiple studies support the notion that viral-genome 
specific elements in the 5’ non-coding region allows the viral 3D polymerase to identify and 
copy only viral RNAs, despite the preponderance of cellular mRNAs (47). Underscoring this 
point is the experimental observation that the homopolymeric tract in the 3’ non-coding region is 
required for RNA synthesis, despite the fact that its length varies from species to species (4). In 
some picornaviruses, ubiquitination of the viral 3D polymerase is also believed to play an 
important role in promotion of RNA synthesis (4). While full length, negative-sense viral RNA is 
necessary to template the formation of additional positive-sense genomes, the two breeds of 
RNA are found in vastly different quantities during viral infection, with positive-sense RNA 
predominating in ratios ranging from 30:1 to 70:1 (48).  
 
Picornaviral interference with host cell processes 
 
 A successful viral infection relies upon the consumption of cellular resources in the form 
of enzymes, energy and other proteins and intermediates such as tRNA. Consequently, nearly all-
viral species have evolved mechanisms to aid in commandeering host resources for viral benefit. 
Picornaviruses have evolved several strategies to inhibit the expression of host genes and protein 
production to tip the metabolic balance in their favor during infection. Acting on four general 
levels: transcription, translation initiation, nuclei-cytoplasmic trafficking and disruption of 
structures that aid in mRNA processing, these inhibitory mechanisms produce profound 
alterations in the host cell which can be observed as Cytotoxic Effect (CPE) during in vitro 
infections (4). The precise mechanisms used to achieve manipulation of cellular resources varies 
by species, but virtually all picornaviruses studied have been documented to employ at least one 
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or more of these tactics, with evolution having selected for many picornaviral proteins which 
appear to have dual functions that involve promoting viral replication, while impeding host cell 
functions that would be detrimental to progeny virion production (49).   
 The 3C polymerase and 3CD precursors of enteroviruses such as PV, have been shown to 
act on transcription factors that affect Pol I, Pol II, and Pol III function (4). Numerous 
picornaviruses have been shown to possess viral proteins such as 2A and L with the ability to 
directly inhibit the cap-dependent translation initiation on which host cells rely via cleavage of 
cap recognition proteins such as eIF4G and eIF4E (50). Cleavage of PABP by the picornaviral 
3C protease plays a role in inhibition of cellular translation and in the transition from viral RNA 
replication to translation (4). Additional inhibition of cellular translation is achieved through 
direct interaction with ribosomes and control of eIF2alpha phosphorylation through modulation 
of the critical protein kinase R (PKR) (51). Disruption of essential nucleo-cytoplamic transport 
has been documented in Enteroviruses and Cardioviruses where the 2A and L proteinase have 
been observed to catalyze the destruction of key nuclear pore complex proteins like Nup 98 and 
Nup 62 (52). Picornaviral induction of cellular mRNA silence and decay is seen in the 
modulation of stress granules (SGs) and disruption of mRNA processing bodies (PBs) (53).  
 
Picornavirus assembly  
 
 Picornaviral particle morphogenesis and cellular egress are the least characterized stages 
of the infectious cycle, and most investigations into these processes have focused upon PV. In 
these studies, initial myristolization of the viral polypeptide P1 segment, and association with 
cellular heat-shock protein Hsp90, is shown to be important for initial steps in P1 organization, 
but 5s pentamer formation after P1 cleavage into VP0, VP1 and VP3 does not appear to require 
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chaperones (4). This 5s pentamer is considered to be the fundamental building block of the 
picornaviral capsid. The subsequent 14s pentamer is composed of 5, 5s pentamers, the formation 
of which is thought to be aided by the presence of the myristic acid association on the N terminus 
of P1 (4). Incorporation of the viral RNA genome has been hypothesized to occur via 
condensation of the 14s pentamers around the viral RNA, or by RNA insertion into an already 
virtually complete capsid structure. Currently, there is no strong evidence for the existence of 
“packing signals” within the viral RNA to guide selective viral genome incorporation for most 
picornaviruses (4). However, interaction between the non-structural 2C-ATPase and capsid 
proteins in Enteroviruses has garnered experimental support as a mechanism that provides 
morphogenesis specificity in this species. Complete capsid formation with failure to insert an 
RNA genome is also believed to occur frequently for some picornaviruses, possibly accounting 
for the large particle-to-PFU ratio seen in many species (4).  
  
Human Rhinoviruses (HRVs)   
 
 While having previously been defined as its own genus, advances in genome analysis 
combined with new taxonomic requirements delimiting genus characteristics, HRVs have been 
reassigned to the Enterovirus genus of the Picornaviradae family (4). While transmission of most 
Enterovirus genus members is characterized by feco-oral or respiratory routes, HRVs are 
distinguished by their tropic restriction to the respiratory mucosa, a characteristic which is likely 
a result of the receptor distribution within the tissues of the host, and documented acid lability 
which does not make them amenable to gastric environments (54). Transmission and tropism 
aside, HRVs share the same predominant picornaviral and enteroviral molecular features 
previously described. Their designation as HRVs is due to the etymology of the root “rhino” and 
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their association with disease affecting the nasal passageways; it is not to be confused with viral 
infections afflicting the mammalian rhinoceros species or the potential zoonotic transmission of a 
rhinoceros-endemic virus to humans.  
 
HRV classification and taxonomy  
 
 With well over a hundred different serotypes, the genetic diversity found within the HRV 
family is staggering. While HRVs have been historically delineated by receptor affiliation, 
advances in sequencing technology have allowed HRVs to be further classified based upon 
genomic phylogeny. Phylogenic analysis has been especially helpful in understanding the newly 
characterized HRV-C, whose association with more severe cases of respiratory distress underlies 
the clinical importance of understanding HRV evolution (55) . Interestingly, receptor preference 
is not exclusive to each genetic clade, with the ICAM-1 receptor being the most proliferatively 
represented. The minor group HRVs which utilize the LDLR receptor are not as well represented 
as their major group counterparts, however, the still have a strong clinical presence (4). 
Distinctions among the 3 different phylogenetic clades are featured prominently in the 5’ UTR 
whose secondary structures play a role in modulation of both translation and transcription. In 
particular, the spacer region immediately 3’ to the cloverleaf structure in the 5’  UTR is found to 
vary in length significantly between the different clades, and also considerably within them. In 
addition, key features of the IRES, whose presence is responsible for recruitment of the 40s 
subunit and initiation of translation, is found to vary considerably among the three clades. The 
amount of HRV type A representatives has led to the further categorization into small groups or 
“clades” which share genetic similarity. One such clade, know as “clade D”, has demonstrated a 
significant amount of clustering and divergence that its possible designation as a new species, 
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“HRV-D”, is being debated (56). Amino acid comparison matrices have also identified clusters 
within the HRV-C and HRV-B species who most likely share a common ancestor. Phylogenetic 
analysis has revealed that HRV-A shares a common ancestor with HRV-C, which is considered a 
sister group to the HRV-B clade (4). The clinical severity of HRV-C makes the intersection of 
HRVA and HRVB, and the resulting phenotype, an important and on-going area of study 
(Diagram 1.3). While the immunological pressure for evolution and variation on exposed 
antigenic regions is expected and observed among these species and clusters, it is also important 
to note that much sequence variability can be seen in non-antigenic regions as well (57). The 
source of this genotype variation among HRVs can be largely attributed to the HRV polymerase 
whose lack of a proofreading mechanism has been cited to result in base-pair mis-incorporations 
with an approximate frequency of once every 10^3 or 10^4 basepairs. This variability has led 
many to use the term “quasi-species” to address the genetic variability inherent in any HRV 
population (58). In addition to constitutive genetic diversity created by the RdRp, additional 
diversity is produced via recombination between different species, mostly likely during instances 
of co-infection. One such HRV that is believed to have evolved via a recombination event is hrv-
46, whose genome has been shown to be largely comprised of hrv-53 and hrv-80 genetic material 





Diagram 1.3 The phylogeny of HRVs  
The three key species of HRV are shown, and their relationship to their parent class, the 
Enteroviruses. The dashed line indicates that HRV-D is not officially distinguished as a species 




 Despite their genetic similarity, HRVs can be further classified into three serotypes based 
upon the cellular receptor used to gain entry into susceptible cells. Endocytic uptake of the virus 
particle is dependent upon successful interaction with the appropriate receptor and ultimately 
results in release into the host cell cytosol by an incompletely described process so that an 
infectious cycle can begin (59).  
 
Receptor classification  
 
 Comprising approximately 90% of HRV serotypes, major group HRVs interact with the 
Intracellular Adhesion Molecule 1 (ICAM1) through a depression or “canyon” around the five 
fold axis of the icosahedron (4). In contrast, minor group HRVs interact with members of the 
Low Density Lipoprotein Receptor (LDL-R), which includes the LDL-R and the LDL-R - related 
protein (60). In addition, while major group HRVs are found to bind within the canyon at the 5-
fold axis of symmetry, minor group HRVs are found to interact with their receptor around the 5-
fold axis of symmetry and may not bind within the canyon itself (4). First described in 2006, 
Rhinovirus C (HRV-C) has been documented to gain cellular entry using the Cadherin Related 
Family Member 3 (CDHR3) receptor (4). While research on this new HRV is ongoing, the 
clinically severe infections in the lower respiratory tract attributed to this serotype may or may 
not be due to receptor tropism and potential preference for the lower respiratory tract (61). 
Despite variation in receptor usage, airway epithelial cells are currently found to be the primary 
targets of HRV infection in clinical investigations, with possible infection of airway 
macrophages that might play a role in inflammation, possible asthma aggravation, and allergen 













Diagram 1.4 Receptors used by viruses. 
 A range of receptors used by viruses demonstrates the degree of conformational variability  
 
 In addition to receptor-based classification, there has also been an attempt to classify 
HRVs based upon drug susceptibility (4). The delineation into group HRV-A or HRV-B is based 
upon sensitivity to a panel of compounds, with minor group HRVs found to exclusively be 
members of HRV-B, the group which has been shown to result in more than twice as many 
severe clinical infections per serotype (63). Studies into the possible structural reasons for these 




 Elegant in it’s simplicity, the rhino viral capsid consists of just 4 distinct proteins whose 
non-covalent and repetitive interaction facilitates the graceful assemblage of a classic 
icosahedron with a triangulation number of 3 (64). Common to all picornaviruses, 60 copies of 4 
proteins: VP1, VP2, VP3 & VP4, form the repeating promoter whose 5-fold axis contains a 
canyon for receptor binding (65). While the comparably small VP4 remains concealed within the 
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capsid structure, VP1, VP2 & VP3 can be seen as three smaller triangle-like structures on the 
surface of each face (26). A final cleavage event where the precursor VP0 undergoes cleavage to 
produce VP4 and VP2 is the final step to producing a mature infectious virion (4). The complete 
icosahedron is composed of 12 pentamers, which are the aggregate of 5 protomers. A single 
protomer consists of 1 copy of each HRV capsid protein (Diagram 1.5). Contributing most of the 
visible surface area, VP1 is located around the five fold axis and contains a wedge-shaped eight-
stranded Beta barrel, known as a “jelly roll”, that is largely responsible for the bulk of the viral 
capsid (66). Additionally, surface loops on this protein contain the principal antigenic sites, 
which can vary considerably. In some HRVS the exact structure of the “canyon” found on the 
VP1 surface is cited to control capsid flexibility and un-coating and assembly constraints (4). 
Interaction of drugs like Win compounds with the canyon can have a locking effect on the capsid 
structure, preventing un-coating (67). Many HRVs also contain a “pocket-factor” a natural fatty 
acid ligand which imbeds in the hydrophobic canyon on the viral capsid surface, a small lipid 
whose association with the viral capsid might play a stabilizing role, however the exact function 
is unknown (68). Described as having “open” and “closed” conformations, this hydrophobic 
canyon formed by the beta barrels of VP1 has been most noted for it’s interaction with the 
antiviral compound pleconaril, whose displacement of the pocket factor and canyon occupation 
is associated with inhibition of capsid functions (69) . Changes in the structure of this canyons is 
believed to be responsible for the Win-drug resistance observed in the recently discovered, and 












Diagram 1.5 Triangulation of the icosahedral capsid.  
The five-fold, three-fold and two-fold axis of the icosahedron are illustrated. The increase in 
triangulation number on the geography of the structural unit illustrated between the T-1 and T-3 
capsid.  
 
 Several loops protruding off of the HRV capsid surface are associated with antigenicity 
and drug susceptibility. Known for its flexibility, the B-C loop is believed to modulate virus-
receptor interactions, especially that of  the major group HRV interaction with ICAM-1, and is 
located around the 5 fold axis of the icosahedron near an ostensible pore structure (4) . Mutations 
within this loop region are thought to modulate host immune system detection and have been 
shown to be involved in the generation of F-12 antibody Fab fragment escape mutants (4). 
Studies where the B-C loops from different strains of PV and coxsackie viruses were swapped 
lead to differential susceptibility of these viruses to neutralizing antibodies, without a dramatic 
effect on the rest of the viral replication cycle. Key differences in the B-C and H1-loops has also 
been cited to play a role in the receptor preference difference between major and minor group 
HRVs (16) . In studies on HRV14 susceptibility to Win compounds, movement of the B-C loop, 
as well as other loops structures on the capsid surface, was shown to occur with Win compound 
binding, despite the distance from the Win compound canyon site (26). Furthermore, mutations 
in the B-C loop have been shown to alter the susceptibility of HRV14 to damage due to proteases 
such as trypsin (71). These observations underscore the importance of the B-C loop in critical 






 Characteristic of all picornaviruses, HRVs posses a single-stranded RNA genome of 
positive polarity containing the general features present among all Enteroviruses. Translation of 
the uncapped rhinoviral genome occurs upon release into the host-cell cytosol and interaction of 
host ribosomes with the IRES within the long 5’ untranslated region(4). This IRES is followed 
by a long open reading frame (ORF) which codes for a self-cleaving polyprotein (Diagram 1.6). 
Cleavage activity of the 2A and 3C proteases result in the production of the P1 polypeptide 
which contains the rhinoviral capsid & enzymatic proteins (4). Like other picornaviruses, HRVs 
are found to have an accompanying VPg protein, whose presence is necessary to template and 
prime the production of viral genome replication. Structurally, the VPg protein of HRVs is found 




Diagram 1.6  HRV genome structure  
The general structure of the HRV ORF is shown. Delineations are representative of the distinct 
proteins post cleavage cascade 
 
 
Rhinovirus receptor binding and cell - entry  
 
 Composed of just nucleic acid and protein with no metabolic source of energy, HRVs do 
not posses the energetic potential to forcibly enter a host cell, and must rely on cell-mediated 
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endocytotic processes to gain entry into their host. Virus interaction with the cellular receptor 
that will trigger its membrane fusion or endocytosis is essential to gain cell entry. These 
receptors used by the virus have other functions relevant to the cell that viruses exploit through 
natural selection. A cell that sports a receptor that has been co-opted by a virus for cell entry is 
described as being “susceptible” to viral infection. The ability of the host cell to provide 
resources that enable the successful completion of the viral infectious cycle is known as 
“permissivity”. Only a permissive and susceptible cell can support natural viral uptake and 
replication (59). For HRVs, susceptible and permissive cells are found in the nasopharyngeal 
tract which the virus gains access to via a respiratory-based transmission process (4). The 
rhinoviral capsid has been documented to “breathe”, a structural distinction that separates it from 
poliovirus. This “breathing” is the mechanistic transition into a 135S particle that involves the 
transient externalization of internal sequences, including the myristolated VP4 and the N 
terminus of VP1. The stable formation of this 135S particle is thought to occur upon major group 
rhinovirus ICAM-1 receptor contact, while minor group rhinovirus transition into a 135S particle 
does not occur until exposure to the lowered pH of the endosome after internalization (73). The 
reasons for this distinction is likely due to the structural differences in the viral capsid that are 
also responsible for the choice in receptor for each group. The details of the receptor-mediated 
endocytic process and genome release of HRVs is not known, but it has been determined that 













Diagram 1.7 Viral Endocytosis.  
The un-enveloped or naked icosahedron is internalized by receptor-mediated endocytosis. 
Interaction with the virus receptor might alter the viral capsid (B: 1-3) and lead to genome 
release as the endosome acidifies. 
 
 The cell entry process for HRVs has been characterized in terms of centrifugation of 
HRV particles whose differential sedimentation is indicative of HRV structural changes. As they 
travel towards the interior of the cell, endosomes experience gradual acidification of their 
interior, a process which is believed to facilitate the “hair-pinning”- like conformational changes 
that allow fusion and release of the endosomal contents into the cytosol (Diagram 1.7) (4). It is 
believed that both major and minor group HRVs primarily exist as 135S particles while 
contained within the endosome, with minor group HRVs only stably taking on this conformation 
as the endosome acidifies (4). Once released into the cytosol, the HRV particles are observed to 
transition into 80S particles, which no longer contain the viral RNA. The noted interaction of 
135S particles with liposomes in the cell cytosol may play a role in triggering the conformational 
transition to the 80S particle (4). The insertion of viral capsid proteins of the extruded 135S 
particle into the liposomes is thought to create, or expand, a pore structure in the capsid which is 












Diagram 1.8 Picornaviruses replication  
The stages of the picornavirus replication cycle are shown as (1) attachment, (2) genome release, 
(3) translation of viral genome, (4) viral polypeptide production, (5) initial polypeptide cleavage, 
(6) use of viral enzymes to facilitate genome replication, (7) use of viral genomic RNA to 
template more RNA replication, (8) creation of -stranded viral RNA to use as templates for + 
stranded RNA, (9) creation of + stranded RNA viral genomes, (10) use of viral + stranded RNA 
as mRNA, (11) secondary cleavage to make viral capsid proteins, (12) capsid assembly, (13) 




 As a single-stranded RNA of positive polarity, the HRV genome can act as mRNA and 
be immediately translated by host ribosomes. In this way, HRVs are not required to come 
equipped with the RNA-dependent RNA polymerase essential for their genome replication; this 
and other necessary proteins are created during the first cycle of translation of viral RNA (75). 
Interaction of the HRV IRES with the host ribosome results in the initiation of HRV translation. 
In addition to being able to operate independently of the cap-binding proteins seen in cellular 
mRNA translation, HRVs also come equipped with proteins capable of interference with host 
cell cap factors, resulting in a predomination of viral RNA synthesis as the infection proceeds 
(4). Having a type 1 IRES, the HRV principally requires just the 40s ribosomal subunit, eIF2-
GTP-met-tRNA, eIFI, or eIF1A for translation initiation. Polypyrimidine-tract Binding protein 
(PTB)- based modulation of HRV translation occurs via the RRM motif, resulting in stimulation 
of HRV translation (76). In HRVs, polyprotein cleavage is primarily mediated by the 2A and 3C 
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proteases in the P1, P2 and P3 segments. Interestingly, some HRV 2A and 3C proteases are 
thought to experience both active and passive nucleo-cytoplasmic transport (4) . 
 
HRV genome replication  
 
 The transition to use viral RNA to template genome synthesis, rather than translation, is 
believed to be mediated by PCBP2 whose increasing numbers as HRV infection progresses are 
due to the production of proteinases 3C and 3CD, whose cleavage of PCBP2 results in its 
preferential interaction with RNA-synthesis initiation factors (77). Characteristic of 
picornaviruses, the amphipathic N-terminal helices of HRV 2B, 2C and 3A proteins are 
responsible for localization of HRV RNA synthesis factories to membranous vesicles within the 
host cells (Diagram 1.8) (28). The structure of the RNA dependent RNA polymerase (RDRP), 
known as 3CDpol for HRV1B, 16 and 14, has been solved via x-ray crystallography. Typical of 
nucleotide polymerases, it is composed of a “right hand” structure with thumb, finger and palm 
domains, with the order of the “finger” regions being the most prominent distinction seen 
between it and that of the PV RDRP (34). The VPg protein plays the role of primer for both 
positive and negative strand RNA synthesis and requires uridylation to form the VPg-pUpU 
complex, a process which is mitigated by the Cis-Acting Replication Elements (CRE) (4). While 
CREs are not unique to HRVs, HRV2A has been documented to posses a novel CRE element 
located within the VP2 region of the ORF, which has not been documented in all picornaviruses 
(78). Elongation of the oligonucleotide involves both double and single stranded intermediates 
on immobilized replication complexes. The debate over the movement of double-strand 




HRV assembly and cell egress 
 
 Studies investigating the process of HRV assembly have produced 80S and 135S 
particles, similar to those seen during cellular entry and capsid un-coating of other 
picornaviruses. Concentration of viral genome replication and production of proteins on 
liposomes is believed to facilitate the formation of the non-ionic repeating interactions of viral 
capsid proteins. During HRV1A assembly within infected HeLa cells 6s, 13s and 14s sub-
particles have been documented, similar to that seen in Enteroviruses (66). The 150S particle is 
believed to contain viral RNA, however, the virion is not considered to be mature until cleavage 
of VP0 to form VP1 and VP4 has occurred. Association of the viral RNA with VP4 or the 
genome-attached VPg protein with VP4 is believed to promote viral genomic RNA entry into the 
capsid (4). The possibility of RNA insertion into a mostly-complete HRV capsid, or HRV capsid 




Immune system detection and antagonism  
 
 While HRV Infection of the nasal-pharyngeal tract results in shedding of the infected 
ciliated epithelial cells, the degree of cytopathic destruction caused by HRVs does not correlate 
to the severity of clinical symptoms documented, especially in the lower airways (80). This 
observation suggests that immunopathologies may play a significant role in the duration and 
severity of HRV infection. To that effect, studies in cultured airway epithelial cells, and other 
cells types, have revealed that each step in the HRV replication cycle is capable of triggering 
various entry-points into the pro-inflammatory pathway whose activity may be responsible for 
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exacerbation of HRV infection symptoms in the upper and lower airway. Unfortunately, 
distinction between major and minor HRVs in their ability to induce various actors in the pro-
inflammatory pathway has not been holistically determined, and at the current date we only 
possess a piece-meal story of pro-inflammatory activity for each HRV type (4) .  
 Through studies with major group HRVs, viral interaction with the ICAM receptor alone, 
has been shown to induce downstream Jun animo-terminal kinase (JNK) and extracellular signal-
regulated kinase (ERK) activity which can modulate interleukin-8, neutrophil chemoattractants 
and other pro-inflammatory cytokines (81). In addition to receptor binding, viral activity within 
the endosome during cellular uptake has been shown to induce NF-kB activity after ICAM 
receptor engagement (82). Furthermore, studies with UV-irradiated HRVs, whose UV-damaged 
genome cannot initiate a replication cycle, only resulted in dampening, rather than abolishment, 
of the HRV-induced IL-8 production in a cultured epithelial cell model (83) . These studies 
demonstrate that viral replication, or generation of replication intermediates, may not be 
necessary for some pathways of innate immune system induction, at least in the HRV subtypes 
studied.   
 As HRV replication commences in the cytoplasm, the double-stranded RNA (dsRNA) 
intermediate necessary for viral genome replication can trigger the host innate response through 
detection by multiple receptors. RIG-I and MDA5, both found throughout the cytoplasm, can 
bind viral dsRNA through carboxy-terminal RNA DExD/H-box domains and interact with beta 
interferon protein simulator 1 through amino terminal caspase activation (84). This activity 
ultimately leads to the activation of IFN-regulated factor 3 (IRF3) and NF-kB transcription 
factors, and lead to downstream induction of interferons and pro-inflammatory cytokines with 
the potential to stem the progression of viral spread. Viral dsRNA binding of Toll-Like Receptor 
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3 (TLR3) is shown to play an analogous role, however it remains localized to endosomal and 
plasma membranes (85). These pattern recognition receptors do not act exclusively on HRVs, 
but TLR3 and MDA5, but not RIG-I, have been found to maximize the innate immune response 
activity against HRVs (4).  
 The presence of an active HRV infection can result in the up-regulation of expression of 
numerous genes that govern the antiviral innate immune response. While an increase in IL-8 
production and an array of neutrophils are the predominant findings of clinical studies using 
nasal secretions and sputum from HRV-infected patients, in vitro studies have revealed the up-
regulation of numerous chemokines, including ENA-78, GRO-alpha, IP-10 and RANTES (86). 
Furthermore, in vitro studies have documented HRV induction of the IFN-beta and -y, 2’, 5’ -
oligoadenylate synthetases, Mx-1, Mx-2 and viperin antiviral proteins (87). 
 As a microcosm of evolutionary biology, it is not surprising that HRVs have developed 
strategies to mitigate the antiviral defenses of infected cells and prevent their detection in the 
host cytosol (Diagram 1.9). To that effect, IPS-1 and RIG-I have been shown to be cleaved by 
HRV proteases 2A and 3C in a HeLa cell model of infection, and proteolytic cleavage of the 
p65-RelA NF-kB subunit by HRV14 has been documented as well (88). Some reports have also 
suggested that HRVs may have a mechanism of degrading MDA-5 and preventing IRF3 
















Diagram 1.9 Viral interactions with cellular immunity mediators  
The interaction of viral replication components with cellular immunity mediators such as Rig-I, 
MDA-5 and Nf-kb, which leads to up-regulation of antiviral genes and the production of an anti-
viral state unless precluded by viral proteins.   
 
 The consistent reoccurrence of HRV infections into late stages of life is testament to their 
ability to evade the production of a sufficient adaptive immune response. While adaptive 
immune responses are mounted during HRV infection, the sheer number of HRVs in circulation 
and the antigenic variability of these highly-mutagenic RNA viruses render adaptive immune 
system defenses non-effective in most cases. Though cross-reactivity has been shown to occur in 
some cases, a high amount of variation in antigenic regions prevents the production of 
efficacious antibodies, and has also stymied attempts to make an HRV vaccine (16).   
    
 HRV infection of the upper respiratory tract is associated with congestion, excess mucus 
production, sore throat, rhinorrhea, sneezing, general malaise and often fever for a period of 5-10 
days (4). Taken together, these symptoms of acute viral rhinophayngitis are colloquially known 
as “the common cold”. While acute viral rhinopharyngitis of numerous etiologies may produce 
the aforementioned symptoms, HRVs have been documented to cause up to 50% of all adult 
cases year-round, with greater predominance in the spring and autumn, in the later of which 
HRVs have been cited to cause up to 90% of cases (4). The exact reasons behind this seasonal 
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pattern are not known, but both ambient air humidity, temperature and social activities, such as 
the return to school in younger populations, has been postulated to play a role (4). While adults 
suffer from 2-3 occurrences of the common cold on average per year, young children and infants 
can experience up to 7-10 episodes per year (4). This discrepancy is believed to be due to 
interaction with fomites or other infected individuals, age-related immune system differences, or 
both (4).  
 
Clinical importance and economic implications  
 
 While generally not of grievous consequence for healthy adult individuals, HRV 
infections have been implicated in the morbidity and mortality of the very young, geriatric, 
immune compromised, or those suffering form other respiratory ailments (4).  
 Infants and young children are known to experience up to 10 episodes of viral-based 
upper respiratory tract infections per year, with HRV being indicted as the most common culprit 
(90). Some studies have cited that up to 26% of children hospitalized with fever and respiratory 
symptoms were HRV positive, a higher percentage of than that of RSV and other respiratory 
viruses that are often considered to be more severe (4). Furthermore, HRV has been found in the 
nasopharynx of up to 40% of acute otitis media cases, an inflammatory disease affecting the 
middle ear that commonly afflicts infants and young children (4). While exacerbation of asthma 
is a frequently cited consequence of HRV infection, this exacerbation is believed to precipitate 
the long-term alteration of airway passages that favor the development of asthma when 
reoccurring episodes of HRV-infection occur early in life (91). In some studies, this correlation 
between recurrent wheeze-inducing HRV infections and acute asthma episodes latter in life was 
stronger than the correlation between aero-allergen sensitization and asthma development (92). 
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The increased morbidity with HRV infection seen in geriatric patients is believed to be a result of 
general immune-system decline and a decrease in alveolar elasticity and elastic lung recoil with 
age. A similar mechanism is believed to account for exacerbations of HRV seen in patients with 
COPD (93). 
   Genetically inherited in an autosomal dominant fashion, Cystic Fibrosis (CF) results in 
mutations that lead to the loss of function of a key transmembrane regulator, leading to the 
production and build-up of thick, detrimental mucus in the respiratory tract. Consequently, viral, 
allergic or bacterial - induced respiratory stress are a leading cause of morbidity and mortality for 
these patients (94). The presence of HRV has been detected in up to 46% of CF patients with 
severe pulmonary exacerbations, and up to 58% of cases of aggravation of airway function, often 
in conjunction with a secondary bacterial infection (95). 
 Allergic inflammation poses a great threat to respiratory function, and the incidences of 
allergy development has experienced a marked increase in developed nations over the past 3 
decades. Recent studies have shown that HRV-induced airway inflammation and sensitization of 
the epithelial tissue layer may promote the formation of respiratory allergies (96). 
 Clinical experimentation detects the presence of HRV 10 hours post-infection with the 
first “burst” of viral release occurring at approximately 48 hours post infection. Under 
experimental conditions with a low MOI, multiple bursts can be observed (4). In addition, 
laboratory experimentation has revealed that HRVs replicate better at a 33C, rather than the 
canonical 37C used in most virology studies (4). This observation supported the theory that HRV 
replication is restricted to tissues of the upper airway, a notion bolstered by the absence of HRV 
in lower airway tissue secretions from clinical isolates (4). However, more recent studies using 
immuno-histochemistry, and in situ hybridization on lower airway bronchial epithelium, have 
 
 35 
detected HRV16 proteins and RNA in these regions (97). Travel to the lower airways is thought 
to be a possible consequence of the recruitment of inflammatory cells and immune responders 
after chemokine production in upper airways and resulting airway responsiveness, but this 
hypothesis has not been proven (98) 
 
Chemical properties of Zn  
 
 Characteristic of a transition metal, Zn can be found in multiple oxidation states, with 2+ 
being the most prevalent in biological systems. In addition to readily forming compounds and 
ligand binding, Zn has been shown to exhibit a hexagonal close-packed crystal structure and is 
diamagnetic (4). As the first member of group 12 on the periodic table, the volatile metals, Zn 
can form alloys readily, the most famous being brass, an alloy of Copper and Zn. In additional to 
its pronounced role in biological systems, Zn is of strong commercial value and is found in 
everything from batteries and shampoos, to paints and electronic components (4). The cultivation 
of this 24th most abundant element on earth for commercial use is believed to have occurred as 
early as the 7th century BC (4). Zn is described as being the most chemically similar to 
Magnesium (Mg) as it is an ion of similar size, also commonly found with a 2+ charge. 
However, despite their chemical similarity, Zn and Mg are very divergent in their degree of 
participation in biological processes, including inhibition of HRVS (99).  
  
The role of Zn in biological processes and enzymatic function   
 
 As a transition metal, Zn is distinguished for the essential role it has been shown to play 
in many biological processes. Crucial for prenatal and post-natal development, Zn is regarded as 
an essential mineral whose deficiency is associated with many diseases. From growth retardation 
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and developmental delays, to increased susceptibility to infections and immune dysfunction, the 
probable role of Zn in vital biological process was long expected before advances in molecular 
biology techniques were available to study its role in detail (99). Zn is now known to play a 
crucial role in the reactive center of over 100 different enzymes, whose catalytic activity depends 
on its availability (4). Stored and transferred as metallothioneins, Zn has been shown to play a 
critical role in the activity of transcription factors, which play a direct role in modulation of gene 
expression. In proteins, Zn is often found to associate with the side chains of amino acids like 
glutamic acid, aspartic acid, histidine and cysteine which may promote its catalytic role (4). The 
presence of a total of 2-4 grams of Zn throughout the average adult human body underscores this 
element’s ubiquitous role in biological processes (4). While research on the many roles of Zn is 
on-going, it is currently believed that at least 10% of all human proteins are capable of 
interacting with the flexible coordination geometry of this lewis - acid (4). However, despite its 
biological necessity, an excess of Zn can result in detrimental physiological outcomes such as 
ataxia and copper deficiency (100). The availability of Zn is strongly linked to the integrity of 
the immune system. Zn deficiency has been shown to dampen both antibody and innate immune 
system responses across the animal kingdom, leading to susceptibility to opportunistic infections 
(4). Zn deficiency mediated T and B cell loss in the bone marrow can result in lymphopenia and 
thymic atrophy, and directly impede the development of immature lymphocytes (101).  
 The zinc proteome comprises an ever-growing database of metalloproteins who rely on 
precise “coordination environments” to effect catalytic activity. The characterization of genetic 
“signatures” in these coordination environments has precipitated the rapid discovery of additional 
Zn binding proteins through high throughput sequencing analysis (276). Zn catalysis sites within 
proteins are generally characterized by three ligands in addition to one water molecule, with 
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additional ligands playing stabilizing roles in some enzymatic species (276). While extensive 
classification of Zn-binding proteins has become a distinct field of study, most binding regions 
can be characterized by the presence of an array of histidines, cysteines and glutamate residues, 
with their arrangement in space playing a deterministic factor rather than one specific sequence 
motif (276).  At present, the four principle classes of metalloprotein catalytic sites are the Class I 
oxidoreductases, Class II transferases, Class III hydrolases and Class IV lyases. Zinc Finger 
Proteins (ZFP), who have been shown to play a nearly ubiquitous role in DNA binding and 
modulation of gene expression, are principally identified by their Class II cysteine and histadine-
rich repeats that form a three dimensional structure that can “grip” DNA (102). Conserved from 
higher lever vertebrates, to prokaryotes, yeast and plants, ZFPs can have one or two binding sites 
comprised of runs of cysteines, histidines, or cysteine alone, of 4 residues or more. The actual 
dissociation constant (Kd) of Zn in ZFP coordination complexes is unknown due to 
physiological complications that are mitigated by variable intracellular environments. However, 
in vitro studies predicated on a single ZFP motif has indicated that the motif might range from 
10^-9  to 10^-11 concentrations (103). The physiological importance and ubiquity of ZFPs in 
biological systems underscores the potential detrimental consequence of deregulation of Zn 
homeostasis within the cell.  
 In contrast to ZBPs, EDTA, a common buffering agent in biological assays, has been 
found to have a Zn Kd is the range of 10^-16. While EDTA is also a chelator of other 2+ cations 
like Mg and Ca, it has been found to selectively deplete solutions of Zn, vastly favoring it over 
other divalent cations. Consequently, EDTA has been found to strip Zn cations from biological 
proteins even under conditions of limited exposure. Furthermore, the dramatic and rapid removal 
of Zn cations from the histidine-rich active sites of some ZBP leads to irreparable damage when 
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the true native structure of these enzymes cannot be re-formed (104). Consequently, EDTA has 
extensively been used to experimentally modulate the bioavailability of Zn in vitro, with high 
enough concentrations able to remove even trace amounts of this metal (104).  
 
Prior research on HRVs and Zn    
 
 In 1974, a general study examining the effect of various metal compounds on viral 
production in tissue culture noted a sharp decrease in HRV infection after HRV infected cells 
were exposed to Zn (105). This observation led to a follow-up study which characterized the 
accumulation of a large picornaviral polypeptides in the presence of Zn ions (106). This 
observation suggested that intracellular Zn ions might play a role in the disruption of the 
polypeptide cleavage events characteristic of picornaviruses. An additional study by Koran and 
Butterworth confirmed this hypothesis, demonstrating inhibition of viral polypeptide cleavage 
during HRV replication when intracellular Zn levels were raised (107). However, it is important 
to note that this polyprotein processing failure in the presence of Zn was not found to be unique 
to HRVs. Butterworth and Koran made these observations in multiple picornaviruses such as PV 
and coxsackie B3 virus (CBV3). Therefore, this mechanism is unlikely to account for the HRV-
specific inhibition initially documented. Fueled by these experimental insights, a group lead by 
Eby et al, conducted the first Zn lozenge clinical trial that demonstrated reduction in the duration 
of the common cold in individuals enrolled in the study (108). However, in this study, the 
etiology of the infectious agent eliciting the “common cold” symptoms was not determined prior 
to enrollment. Therefore, the decrease in duration of the symptoms experienced by lozenge users 
cannot be directly attributable to HRV inhibition.  
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 In 1987, work performed by Geist et al. discounted the research of Eby and Butterworth 
by demonstrating that the levels of intracellular Zn necessary to observe HRV inhibition were 
cytotoxic to the HeLa and WI -38 cells infected. Furthermore, they determined that the level of 
Zn needed to see viral inhibition greatly exceeded that seen in normal human serum after lozenge 
administration (109). However, additional work investigating the potency of a number of 
different Zn compound demonstrated that the amount of free Zn+ in solution and HRV2 
inhibition held a linear relationship, with no reported cytotoxicity (110). Around the same time, 
immunological studies reporting the potentiation of interferons by Zn offered a different 
explanation for success seen in some clinical trials (101) . 
 Clinical trials aside, no in vitro experimental investigation into the potential inhibitory 
properties of Zn alone on HRVs has been reported in over two decades. However, studies using 
Zn in conjunction with chelating and ionophoric agents has been conducted (4). In all of these 
studies, one of the salient findings has been the dependency on Zn availability within the cell to 
observe antiviral activity. Intracellular inhibition of HRVs and other picornaviruses was seen 
with pyrithione (PT) and hinokitiol (HK) only when sufficient Zn was present, and the inhibitory 
potential of pyrrolidine dithiocarbamate (PDTC) was only observed when Zn+ or Cu+ was 
present (4). In both of these studies inhibition of polyprotein processing was cited as a key 
mechanism of viral inhibition (111). However, the unnatural amount of Zn+ and ionophore 
concentrations needed within an infected cell to witness inhibition of viral replication makes the 
relevancy of these mechanisms doubtful. Furthermore, the additional observations of multiple 
viral protease failure and truncation of RNA synthesis, suggests that this decrease in virion 
production may be due to the generalized effect of cell distress due to detrimentally elevated 
cation levels. Finally, in the two studies which present association with and disruption of 
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polyprotein processing as the possible mechanism of Zn inhibition, other picornaviruses were 
either not tested, or shown to experience the same type of inhibition when exposed to unnaturally 
high levels of intracellular Zn, or Zn in conjunction with ionophores. Therefore, even if 
abnormally high intracellular Zn levels can disrupt polyprotein processing, this mechanism is 
unlikely to account for the very HRV-specific inhibition documented in prior studies, and 
investigated in this body of research.  
 Despite discrepancies in experimental findings, numerous clinical trials using a variety of 
Zn lozenge formulations were conducted over the next two decades with disparate outcomes. 
However, attempts to perform meta-analyses on clinical trial outcomes from different studies 
also resulted in divergent outcomes, presumably due to the parameters used to determine the 
studies included, and the statistical models used to model the data (112). The most recent and 
comprehensive meta-analysis conducted in 2015, concluded that Zn gluconate lozenges are 
effective if use commences within 24 hours of the onset of symptoms (113).  
 Despite the lack of a descriptive mechanism of Zn antiviral activity or consistently 
decisive clinical trials, numerous entities have seized upon the commercial opportunity to bring 
various Zn-based products to market, claiming that they have the potency to relieve the common-
cold sufferer. As a testament for the demand for common-cold therapeutics, the profitability of 
these products have experienced undisputed growth (114). Even with the negative publicity 
garnered by the makers of Zicam, with patient claims of permanent nasal sensory damage, the 
demand for Zn-based products has not diminished, even after studies carried out in rats revealed 
that excess Zn exposure could have a detrimental impact on the olfactory neuroepithelium (115). 
The resounding financial success of these controversial products can most likely be attributed to 
the large population of common-cold sufferers with discretionary income whose desperation for 
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symptom relief supersedes the lack of medical consensus as to their viability. It follows then, that 
the development of a scientifically substantiated treatment for the common cold would garner 
even greater public appreciation and commercial success.  
 
Summary and scope of research  
 
 In this study I have examined the role of Zn in antiviral inhibition when applied to HRVs 
in isolation. In prior studies, the application of Zn to HRV-infected cells yielded inhibitory 
results, but the experimental design used did not allow for the examination of HRVs and Zn in 
isolation.  The dampened HRV production could not be directly attributed to Zn due to the 
potential cellular stress, or alteration of normal innate immune functions, that could have also 
played a role in the abrogation of HRV production. Furthermore, many of these studies were not 
HRV-specific. Given the physiological constraints of nasal spray or lozenge use, I hypothesized 
that the majority of any Zn-based inhibition attributable to these products was likely to occur 
through extracellular contact of these therapeutics with HRVs. To test this conjecture, I designed 
a series of experiments that examined the effect of Zn on HRVs in isolation and demonstrated 
that extracellular exposure to Zn alone is sufficient to decrease the infectivity of an HRV 
population. I then demonstrated the specificity of this mechanism for HRVs and Zn, and 
characterized the mechanism behind this profound abrogation of HRV infectivity after Zn 
exposure. Through the cultivation of Zn-resistant mutants, I was able to characterize 
topographical areas of the viral capsid that might lend Zn susceptibility and prevent the Zn-
mediated damage to HRV RNA observed. Furthermore, I also demonstrated the ability of Zn-
ionophore complexes to facilitate extracellular inhibition of HRVs using lower Zn concentrations 
than that required in Zn-based inhibition alone. 
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 Since it was first described in 1974, the potential of Zn to inhibit HRVs has inspired 
numerous clinical trials and the production of Zn-based products with dubious efficiency. Here I 
have attempted to demonstrate and describe a mechanism of Zn inhibition of HRVs that is viable 
in the context of Zn lozenge or nasal spray use and might explain the successes seen in some 
clinical trials. It is my hope that the results of these studies might template the design of more 





   
 
  
CHAPTER 2: MATERIALS AND METHODS  
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Cells, viruses and plasmids 
 
The HeLa S3 and H1 (human cervical carcinoma) cell lines were maintained in Dulbecco’s 
modified essential medium (DMEM; Life Technologies, Carlsbad, CA) supplemented with a 1% 
penicillin-streptomycin solution (Invitrogen, Carlsbad, CA) and 10% bovine calf serum 
(HyClone, Logan, UT). Cells were maintained at 33-37C and split using trypsin (Gibco) 
regularly (70-90% confluence). The pACYC177-Xmal-T7-WT-RV1A-Xho1 plasmid was 
harvested from One Shot® TOP10 Chemically Competent E. coli (Life Technologies/Invitrogen 
cat# C4040-10) using a QIAGEN Plasmid Midi Kit (cat# 12143), following the manufacturer’s 
protocol after transformation using the manufacturer’s protocol and incubation at 37C overnight 
with constant agitation in standard LB broth (10g Bacto-tryptone, 5g yeast extract,10g NaCl (pH 
7.5 in 1000ml) supplemented with 1000 mg/ml ampicillin.  
Poliovirus was isolated from HeLa cells transfected with in vitro synthesized RNA using 
lipofectamine (Invitrogen) (32, 33). These stocks were fractionated into aliquots to minimize the 
number freeze-thaw cycles and kept at -80C  
HRV16, HRV39, HRV1A, and Coxsackievirus B3 
 
HRV16, HRV39, HRV1A, and Coxsackievirus B3 were isolated from HeLa cells transfected 
with in vitro-synthesized RNA (34-36). All in vitro- synthesized RNAs were transcribed from 
linearized templates using T7 RNA polymerase and following the manufacturer’s protocol 
(Promega, Madison, WI). These stocks were aliquoted to minimize the number freeze-thaw 
cycles and kept at -80C.  




Stock solutions of 0.1M EDTA, pH 8.0 (Sigma), 0.1M ZnCl2 (Sigma), 0.1M Zn aspartate 
(Sigma), 0.1M Zn gluconate (MP Biomedicals, Santa Ana, CA), 0.1M MgCl2 (Sigma), 0.1M 
MnCl2 (Sigma), 0.1M CaCl2 (Sigma), 100mM -.1uM Pyrithionine (Sigma), 100um-.1M 
Hinokitiol (Sigma) and 100um -.1M PDTC (Sima) were prepared in 1X phosphate buffered 
saline (PBS) pH 7.4 or double distilled water pH 7.4 (Millipore, Billerica, MA). All solutions 
were filtered through a 2⎧M filter (Millipore) before use in cell culture. All ionophores and Zinc 
salts were purchased from Sigma Aldrich. Solutions were kept at 4C.  
Zn Treatment  
 
Zn solution was added to viral sera to achieve the concentration desired. PBS (Life Technologies 
cat# 21600-010) was used to control for volume in untreated samples. After addition of Zn, the 
samples were inverted 2-5 times and then placed on nutator at 37C, or 4C in the case of 
temperature based studies.  
Plaque assays.  
 
To determine the titer of PV and EV68, virus dilutions were prepared in virus binding buffer 
(VBS, 1X PBS supplemented with 0.01% bovine serum albumin). 100ul of each dilution was 
used to infect the confluent monolayer on a 6-well flat bottomed plate where each well contained 
9.5cm^2 surface area (Falcon). The plates were incubated with periodically agitation at 37C for 
45 minutes. After incubation, HeLa cells were covered with 2ml of an overlay consisting of 
DMEM (Millipore 122  Fisher, Billerica, MA), 0.2% NaHCO3 (Sigma, St. Louis, MO), 5% 
bovine calf serum, 1% penicillin-streptomycin and 0.9% bacto-agar (Fisher Scientific, Carlsbad, 




To determine the titer of HRV16, HRV39, EMCV, and Coxsackievirus, virus dilutions were 
prepared in virus binding buffer (VBS, 1X PBS supplemented with 0.01% bovine serum 
albumin). 100ul of each dilution was used to infect the confluent monolayer on a 6-well flat 
bottomed plate where each well contained 9.5cm^2 surface area (Falcon). The plates were 
incubated with periodically agitation at 37C for 45 minutes. HeLa cells were covered with 2ml of 
an overlay of DMEM, 0.2% NaHCO3, 1% bovine calf serum, 1% penicillin- streptomycin, 0.1M 
MgCl2 (Sigma) and 0.8% Noble agar. After the overlay solidified, it was covered with 2ml 
liquid medium consisting of DMEM, 0.04 M MgCl2, 0.002% glucose (Sigma), 0.1% bovine 
serum albumin (Sigma), 2 mM sodium pyruvate (Invitrogen), 4mM glutamine (Invitrogen), 
4mM oxaloacetic acid (Sigma), 0.2% NaHCO3 and 1% penicillin-streptomycin. Cells were 
incubated for 72-96h and developed using 10% trichloroacetic acid and crystal violet.  
To determine the titer of HRV1A and HRV2, virus dilutions were prepared in virus binding 
buffer (VBS, 1X PBS supplemented with 0.01% bovine serum albumin). 100ul of each dilution 
was used to infect the confluent monolayer on a 6-well flat bottomed plate where each well 
contained 9.5cm^2 surface area (Falcon). The plates were incubated with periodically agitation 
at 37C for 45 minutes. 2ml of the HRV1A plating medium composed of DMEM supplemented 
with 2% bovine calf serum, 40mM MgCl2, 0.01% NaHCO3, 1% penicillin-streptomycin and 1% 
low-gelling type VII agarose (Sigma) was applied after incubation. Cells were incubated for 96-
120h and developed using 10% trichloroacetic acid and crystal violet.  
ICPA Assays  
 
Infectious Center plaque assays were performed using the same HeLa cells and HRV1A and PV 
stocks previously described. 100 ul of HRV1A and PV stocks were used to infect a monolayer of 
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HeLa cells which were held at 4C for 20 -45min by keeping the HeLa dishes on ice and 
monitoring the temperature using a thermometer. The plates were cooled to 4C prior to infection 
and kept at 4C through the viral infection, centrifugation and washes. After the incubation 
period, the remaining viral inoculate was removed and the plates were washed 3 times with PBS 
that had been cooled to 4C. Following the washes, these cells were harvested mechanically using 
a cell scraper and gently pipetted into a centrifuge tube and spun at 200 rpm for 5 min at 4C. 
Excess supernatant was removed and the cells were gently resuspended in cooled 4C PBS,  
underwent serial dilutions, also in PBS, and 100 ul of each dilution were plated on a second 
mono-layer of HeLa cells. Following a 30 min incubation period at 37C,  2ml of a semi-solid 
agarose overlay was applied that was identical in composition as that used for traditional 
HRV1A or PV plaque assays. After a 96 -144 hr incubation period (HRV1A) or 72-96hr 
incubation period (PV), the 10% trichloroacetic acid was applied to the ICPA for at least 20 
minutes to fixate the HeLa monolayer and followed by staining with crystal violet solution and 
subsequent washing in the same manner as a traditional plaque assay.  
 
Competition Assays  
 
Confluent monolayers of HeLa cells in 60mm dishes were infected with a mixture of untreated 
and Zn-treated HRVIA  with the amount of untreated HRV1A held constant. The approximate 
PFU per 50ul aliquot of untreated HRV1A was determined. This amount of untreated HRV1A 
was held constant while increasing amounts of Zn-treated HRV1A was added to the inoculate 
mixture. The 100ul volume of each inoculate was kept equal by using DMEM to make up the 
difference when the maximum amount of Zn-treated HRV1A was not used. These 100ul 
inoculate mixes were used to infect each well of HeLa cells and held at incubation at 37C for 
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45min with intermittent agitation. An identical procedure was used for competition between 
untreated HRV1A and UV-inactivated HRV1A 
.  
UV-inactivated HRV1A  
 
500ul aliquots of untreated HRV1A was applied to 10cm dishes and spread into a thin layer. 
These dishes were then subjected to UV irradiation for 7 minutes in a Stratalinker 2400 
(Stratagene, LaJolla, CA). Confirmation of complete inactivation of the HRV1A population 
using this method was achieved by performing a  traditional plaque assay using 100ul of each 
500ul treatment group.  
 
Northern Blot Hybridization Analysis 
  
Viral RNA was fractionated in 1% agarose containing 6% formaldehyde in 1X MOPs buffer. 
After electrophoresis at approximately 85-95 volts for 1.5-2 hours, lanes containing RNA 
markers were excised and viewed on a UV transilluminator to confirm the presence of RNA, the 
remainder of the gel was moved to a capillary transfer apparatus and RNAs were transferred to a  
positively charged nylon membrane (Roche) in 2x SSC buffer overnight. Following transfer to 
the membrane, RNA was cross-linked to the membrane in a Stratalinker 2400 (Stratagene, 
LaJolla, CA) for 25-50 sec and then the membrane was baked at approximately 80°C under 
vacuum for 2-3 hours, pre-  hybridized, and then hybridized with a digoxigenin-labeled DNA 




Digoxigenin DNA probe synthesis and preparation 
 
A digoxigenin DNA probe for HRV1A RNA was synthesized using a DIG labeling and detection 
(Roche, Indianapolis, IN) with custom HRV1A primer sets to produce a 500 bp-800bp DNA. 
Prior to addition to hybridization solution, the DIG probe was boiled for 10 minutes and then 
immediately chilled on ice to promote double stranded DNA separation. A random-hexamer 
primed Digoxigenin probe was also made using randem hexamers Life Technologies (cat # 
N8080127) and the PyACY-HRV1A plasmid.  
 
Isolation of viral RNA 
 
Virion RNA was isolated from virus particles produced by ultracentrifugation of infected cell 
supernatants in an SW28 rotor at 28,000 rpm for 3h at 4°C. Supernatants were discarded, and 
pellets were pooled and suspended in 500ul of DMEM or PBS  An equal volume of TRIzol LS 
reagent (Ambion/RNA, Life Technologies) and RNA was extracted according to the 
manufacturers’ protocol, and RNA pellets were resuspended using 12-20ul of  DepC (Sigma 
Aldrich)-treated water.  
Sucrose gradient HRV1A purification 
 
HRV was fractionated on sucrose (Sigma Aldrich) gradients (5% to 45% w/v) at 40,000 rpm for 
2 hr after application of  500ul of .2uM viral Sera was carefully added to the top of the column . 
Fractions of 0.5 ml were collected from the top down and stored at - 80°C before assaying for 
viral infectivity and viral RNA.  
Native Gel Analysis  
 
Aliquots of sucrose gradient fractions were applied to an 8-12% native gel matrix and subjected 
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to electrophoresis at 40-90V at 4C for 3-6 hours. Following transfer to a an Amersham hypofilm 
(GE Healthcare)  membrane using a Bio-Rad vertical transfer apparatus overnight, the membrane 
was probed using a Coomassie Blue (Sigma Aldrich) procedure  or silver-stain procedure 
(Ambion) using the manufacturer’s protocol.  
Denaturing SDS-PAGE Gel Analysis   
 
Aliquots of sucrose gradient fractions were applied to an 10-12% SDS PAGE gel matrix and 
subjected to electrophoresis at 60-90V at 4C for 1.5-2.5 hours. Following transfer to a membrane 
using a Bio-Rad vertical transfer apparatus overnight, the membrane was probed using a 
Coomassie Blue procedure  or Silver-stain procedure (Ambion).  
Reverse Transcription of viral RNA and DNA 
 
 RNA isolated by Trizol was resuspended in DepC-treated water. Approximately 10 μl or 2 μg of 
RNA was used to template DNA synthesis by SuperScript III reverse transcriptase and was 
primed with random hexamers according to the manufacturer’s directions (Invitrogen, Carlsbad, 
CA).  
 
Primer design, sequencing and sequencing analysis 
 
HRV1A primers for genome synthesis were designed using APE (A Plasmid Editor) open-source 
software. Fifteen primer pairs were designed to produce overlapping amplicons of approximately 
500 bp, and these primer pairs were optimized for similar Tm values, enabling the production of 
longer amplicons if used together (Figure 2.1). A list of primers used can be found in 
Supplementary Table 1. PCR was performed with Herculase polymerase (Agilent Technologies, 
Santa Clara, CA) using the manufacturers’ standard protocol aside a lower binding temperature 














Figure 2.1 Primers used to sequence the full-length HRV1A genome.  
Using A Plasmid Editor (APE) software, 15 pairs of over-lapping primers were designed whose 
compatible Tms allow for flexible targeting of any region of the HRV1A genome as any 
Forward primer can be used with any Reverse primer. Each pair was tested and yields an 
approximately 500-600 bp product when used with Herculase Taq polymerase with the PCR 
protocol described in Materials and Methods pg  
 
Creation of mutant clones 
  
The following procedure outlines the steps taken to make the mutant clones of HRV1A by 
introducing the mutations found in Zn-resistant isolates. The initial template was the 
pACYC177-Xmal-T7-WT-RV1A-Xho1 plasmid.   
1. PCR using mutagenesis primers over mutation site “a1” & “B2” and “A2” & “b1”. 
     - yields two linear amplicons each containing the mutagenesis site with 
overlapping           mutagenesis regions   
     - Final product needs to be inserted back into plasmid so the “A” & “D” primers 
were          be designed to end at or near a restriction site/ contain the restriction site   
     1a) Confirm amplicon presence and size on gel  
     1b) Harvest, Purify & Quantify (Zymogen gel purification kit, Nanodrop)  
     1c) Confirm mutagenesis site was successful via sanger sequencing (Genewiz) 
 
2.  PCR using amplicons from round 1 as template using primer pair A/D    
     - the complimentary ends of the first round of PCR amplicons hybridize and the final 
product        with the desired mutation was created 
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     2a) Amplicon was check on gel for presence and size 
     2b) Harvest, Purify & Quantify (Zymogen gel purification kit, Nanodrop) 
     2c) Confirm mutagenesis site was successful via sanger sequencing (Genewiz) 
  
 
3. Digestion of amplicon from step 2 and the destination vector (pACYC177-Xmal-T7-WT-
RV1A-Xho1) using restriction endonucleases Sac1 HF & Sfo1.   
 
4. Purification of digested vector and amplicon from step 3 (phenol-choroform or Zymogen 
DNA     clean-up kit) 
 
5. Ligation of digested vector and amplicon from step 4 using T4 DNA ligase at 4C 
overnight       (New England Biolabs)   
 
6. Confirmation of successful ligation and site directed mutagenesis by gel visualization and  
followed by sanger sequencing (Genewiz,) .  
 
   
The primers designed for site-directed mutagenesis are shown below.  
Pair 1 
Forward: 5' CATCACACTACATCAAAATCTGCCCCACTTTTAG 3’ 
Reverse: 5' CTAAAAGTGGGGCAGATTTTGATGTAGTGTGATG 3’ 
 
Pair 2 
Forward: 5' GTCATCACACTACATCAAAATCTGCCCCACTTTTAGATG 3’ 
Reverse: 5' CATCTAAAAGTGGGGCAGATTTTGATGTAGTGTGATGAC 3’ 
 
Pair 3  
 Forward: 5' GTCATCACACTACATCAAAATCTGCCCCACTTTTAGATGC 3' 




PCR was performed using Herculase (Ambion) and the accompanying recommended protocol 
with the adjustment of a lower binding temperature (51-54C) to accommodate the Tm of the 
HRV1A primers in a ThermoCycler ( Fischer  Model number            ) 




 PCR amplicons were visualized and isolated on 10% agarose gels ( Sigma Aldrich ) 
supplemented with Ethidium Bromide ( Sigma Alderich). After subjected to electrophoresis for 
5-1.25 hrs, the amplicons were visualized on a UV-transilluminator . A 500bp ladder was used to 
confirm the size of the amplicons (Fermantos O’ Gene Ruler) When purification was necessary 
prior to sequencing, the gel slices corresponding to the amplicon were excised using sterile 
razorblades. The DNA from these gel slices were then extracted from the gel using a Zymogen 
Gel Extraction kit columns, following the manufacturers protocol. The final elution was 
performed with 12-20ul of sterilized H20 or TE buffer ( 1M Tris-HCl, pH 7.5 or 8.0,10 mM2 
ml0.5M EDTA, pH 8, in 988 ml ddH2O).  
Sequencing  
 
Sanger sequencing of samples was performed by Genewiz (South Plainfield, NJ).  Both 
consensus sequence text files and raw data files were returned for analysis. The samples were 
prepared with 2uM of each primer according the Genewiz protocol.  
Transfection of mutant clones 
 
 A TransIT-HeLaMonster Transfection Kit (Mirus Fisher) was used to with viral RNA 
synthesized using T7 High Yield RNA Synth Kit (New England Biolabs) with H1 HeLa cells. 
Analysis of Results   
 
A Bash shell scripting pipeline was written to uniformly extract, process and format each 
sequencing output using the consensus sequence supplied by Genewiz. This text-file output was 
then aligned using APE (A Plasmid Editor) open-source software. The sequences were aligned to 
both the HRV1A plasmid on which which the primers were templated and to the official NCBI 
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sequence. When discrepancies were found in mutant strains, the raw data file from Genewiz was 
consulted to confirm that the base-pair in the consensus sequence was soundly chosen. The 
resulting polypeptide sequence for each region containing deviations from the wild type 
sequence was generated using the following code. Wild-type sequences and control sequenced 
Genewiz isolates were used for comparison. Additional exploration into the potential impact of 
alterations in amino acid sequence was performed through assignment of each amino acid to it’s 
integer corresponding the biochemical Janin, Kyte-Dolittle or E.Weis value that is a  quantitative 
expression of hydrophobicity, size and chemical reactivity. Alignment and plotting of this string 
of integers revealed the potential severity biochemical change at certain amino acid sites within 
the VP1 polypeptide. 
gencode = { 
    'ATA':'I', 'ATC':'I', 'ATT':'I', 'ATG':'M','ACA':'T', 'ACC':'T', 'ACG':'T', 'ACT':'T', 'AAC':'N', 'AAT':'N', 'AAA':'K', 
'AAG':'K', 'AGC':'S', 'AGT':'S', 'AGA':'R', 'AGG':'R', 'CTA':'L', 'CTC':'L', 'CTG':'L', 'CTT':'L', 'CCA':'P', 'CCC':'P', 
'CCG':'P', 'CCT':'P','CAC':'H', 'CAT':'H', 'CAA':'Q', 'CAG':'Q', 'CGA':'R', 'CGC':'R', 'CGG':'R', 'CGT':'R','GTA':'V', 
'GTC':'V', 'GTG':'V', 'GTT':'V','GCA':'A', 'GCC':'A', 'GCG':'A', 'GCT':'A', 'GAC':'D', 'GAT':'D', ‘GAA':'E', 
'GAG':'E','GGA':'G', 'GGC':'G', 'GGG':'G', 'GGT':'G','TCA':'S', 'TCC':'S', 'TCG':'S', 'TCT':'S','TTC':'F', 'TTT':'F', 
'TTA':'L', 'TTG':'L','TAC':'Y', 'TAT':'Y', 'TAA':'_', 'TAG':'_', 'TGC':'C', 'TGT':'C', 'TGA':'_', 'TGG':'W'} 
janin_code = { 
    'I': 0.7, 'F': 0.5, 'V': 0.6, 'L': 0.5, 'W': 0.3, 'M': 0.4, 'A': 0.3, 'G': 0.3, 'C': 0.9, 'Y': -0.4, 'P': -0.3, 'T': -0.2, 'S': -0.1, 'H': 
-0.1, 'E': -0.7, 'N': -0.5, 'Q': -0.7, 'D': -0.6, 'K': -1.8, 'R': -1.4} 
kd_code = { 
    'I': 4.5, 'F': 2.8, 'V': 4.2, 'L': 3.8, 'W': -0.9, 'M': 1.9, 'A': 1.8, 'G': -0.4, 'C': 2.5, 'Y': -1.3, 'P': -1.6, 'T': -0.7, 'S': -0.8, 
'H': -3.2, 'E': -3.5, 'N': -3.5, 'Q': -3.5,'D': -3.5, 'K': -3.9, 'R': -4.5} 
ew_code = { 
    'I' : 0.73, "F" : 0.61, 'V': 0.54, 'L': 0.53, 'W': 0.37, 'M': 0.26, 'A': 0.25, 'G': 0.16, 'C': 0.04, 'Y': 0.02, 'P': -0.07, 'T': -
0.18, 'S': -0.26, 'H': -0.40, 'E': -0.62, 'N': -0.64, 'Q': -0.69, 'D': -0.72, 'K': -1.10, 'R': -1.8} 
def translate_dna(dna): 
    last=len(dna)-2 
    print(last) 
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    polypep="" 
    for base in range(0,last,3): 
        codon=dna[base:base+3] 
        print("Codon:",codon) 
        amino=gencode.get(codon.upper(), 'X') 
        print(amino) 
        polypep+=amino 
    print(polypep) 
    return(polypep) 
 
def janin_scale(polypep): 
    janin_points = [] 
    for aa in polypep: 
        janin = janin_code.get(aa) 
        print(janin) 
        janin_points.append(janin) 
    print("\n Janin_points:", janin_points ) 
    return [janin_points] 
 
def kd_scale(polypep): 
    kd_points = [] 
    for aa in polypep: 
        kd = kd_code.get(aa) 
        print(kd) 
        kd_points.append(kd) 
    print("\n Kyte and Doolittle points:", kd_points) 





    ew_points = [] 
    for aa in polypep: 
        ew = ew_code.get(aa) 
        print(ew) 
        ew_points.append(ew) 
    print("\n Eisenberg Weis points:", ew_points) 
    return [ew_points] 
 
dna=input("Paste Sequence for Translation Here:") 
dna=dna.upper() 
translate_dna(dna) 




Pymol 3-dimensional Molecular Imaging  
 
Images produced using MacPymol with PDB file 1r1a.pdb. Full and half capsid 
coordinates are from VIPERdb (viperdb.scripps.edu).  
Hinokitiol Treatment  
 
HK in solution was added to viral sera to result in the concentration desired or mixed with Zn via 
inversion and vortexing. PBS was used to control for volume in untreated samples. After 
addition of HK, the samples were inverted 2-5 times and then placed on nutator at 37C, or 4C in 





PT in solution was added to viral sera to result in the concentration desired or mixed with Zn via 
inversion and vortexing. PBS was used to control for volume in untreated samples. After 
addition of PT, the samples were inverted 2-5 times and then placed on nutator at 37C, or 4C in 
the case of temperature based studies.  
PDTC Treatment  
 
PDTC in solution was added to viral sera to result in the concentration desired or mixed with Zn 
via inversion and vortexing. PBS was used to control for volume in untreated samples. After 
addition of PDTC the samples were inverted 2-5 times and then placed on nutator at 37C, or 4C 
in the case of temperature based studies.  
PDTC- Zn Compound Synthesis 
 
30uM or 60uM PDTC and 30uM Zn were mixed, vortexed and left at room temperature or 
heated up to 60C for 20-60min. The precipitate was spun down on a table-top centrifuge and the 
supernatant was removed. The precipitate then underwent 1-3 additional washes involving re-
suspension in distilled water and centrifugation.    
Rnase Inhibtion 










Exposure to Zn+ salts inhibits HRV infectivity 
 
 Previous studies on the inhibition of HRV replication by Zn+ examined the effect of 
adding the cation to infected cells (106). However, when I attempted to replicate the conditions 
seen in some of these studies, I observed that Zn+ exposure was toxic to HeLa and TE cells at 
the amounts necessary to achieve high intracellular concentrations. This cytotoxicity of 
intracellular Zn was also noted in prior studies (109).  Consequently, I chose to take an 
alternative approach, and postulated that any physiologically relevant mechanism of Zn-based 
inhibition relying on lozenge or spray use as a vehicle of delivery was most likely to be 
successful during the extracellular stage of the viral replication cycle, before virions had attached 
and entered a susceptible and permissive cell. Therefore, I hypothesized that there might possibly 
be an extracellular mechanism of Zn-mediated HRV inhibition that might account for the 
successes seen in some clinical trials. I chose to test this hypothesis by exposing HRVs to Zn+ 
compounds prior to their exposure to susceptible and permissive cells using the general 
experimental work-flow shown below, which involved treating HRVs in isolation with Zn 
compounds, prior to serial dilution and inoculation of a confluent monolayer of susceptible and 
permissive HeLa cells. To assay for infectivity of the treated virus particles, a plaque assay was 
performed, wherein a semi-solid agarose overlay is applied to the infected monolayer that 
effectively restricts diffusion of the progeny virions after the lysis of infected cells.  This results 
in punctate regions of cell death, or “plaques”, that can be observed after fixation and staining of 
the remaining monolayer, after an appropriate incubation period that is predicated upon virus 
type. Due to serial dilution of the initial inoculate, ultimately, distinct, countable plaques can be 
observed and used to calculate the original titer of infectious virus in the untreated and Zn-

















Diagram 3.1 Experimental work-flow for Zn sensitivity  
Aliquots of virus were exposed to varying quantities of different Zn+ compounds (Zn-Gluconate, 
Zn-Chloride & Zn-Aspartate), subjected to a period of incubation, and then aliquots of each 
dilution were used to infect HeLa cells. Viral titer was ultimately visualized using the 
appropriate plaque assay protocol for each virus type after fixation and crystal violet staining. 
 
 
 The resulting cytotoxicity from prolonged exposure to high Zn concentrations was 
observed via fixation of HeLa cell monolayers and crystal violet staining, after which both a 
decrease in cell number and the preponderance of inclusion bodies and other signs of a moribund 
cellular state could be readily observed under a standard tissue-microscope (data not shown). As 
obligate intracellular parasites, viruses require the resources provided by an active cellular 
metabolism to complete infectious cycles that result in the production of infectious progeny 
virions. Consequently, perishing cells are unable to support a normal level of viral replication, 
and can therefore lead to a decrease in total viral yield if infected, which might generate a “false-
positive” result when comparing viral titers. Therefore, it was important to confirm that the 
dilution process inherent in the plaque assay procedure successfully diluted the Zn concentration 
in the treated viral samples to a degree that was no longer detrimental to the HeLa cell 
monolayer. To establish that the titers observed from Zn-treated HRVs were not attributable to a 
decrease in HeLa cell metabolism due to any residual Zn present after dilution, identical Zn 
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dilutions, sans virus, were applied to previously infected HeLa monolayers. With no comparable 
decrease in titer seen at even the lowest Zn dilution compared to the Zn-free control infection, I 
was able to conclude that the dilution of the original Zn-treated sample effectively eliminated 
any significant detrimental impact on the cells which might lead to a misleading decrease in viral 
titer in Zn treated groups (Figure 3.1). In addition, HeLa cells were subjected to virus-free 
incubation in Zn-spiked PBS under identical inoculation conditions and then observed for 
morbidity under a standard tissue-culture microscope over a period of 5 days while being 













Figure 3.1 Effect of Residual Zn after dilution 
Untreated HRV1A (0) was compared to HRV1A subjected to 5 mM ZnG (ZnG), and to the titer 
of untreated HRV1A wherein dilutions of 10mM ZnG were added post-infection to the agarose 
overlay for long-term exposure (ZnG dilutions). Virus titers were determined by a plaque assay 
on a monolayer of HeLa cells. 
  
Using the procedure outlined in Diagram 3.1, I demonstrated that the addition of 
Zn gluconate (ZnG) or Zn chloride (ZnCl) to stocks of HRVs prior to infection of HeLa 
cells leads to a decrease in the virus titer as determined by plaque assay, that cannot be 
attributed to cell death due residual Zn (Figure 3.2). Viral infectivity was reduced greater 
than 90% by incubation with 2-10 mM ZnCl or ZnG, with 10mM ZnG consistently 
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rendering almost complete abrogation of viral infectivity (Figure 3.3). While both major 
and minor group HRVs were shown to experience inhibition with Zn treatment, I found 
that HRV1A demonstrated the most susceptibility. HRV16 required the greatest amount 
of Zn exposure to experience inhibition of all the HRVs tested. The reason for this 
discrepancy is unclear, but believed to be unrelated to the difference in cellular receptor 
used to gain entry, given that other major group HRVs demonstrated Zn sensitivity 
similar to that of HRV1A. After initial experimentation with ZnCl, Zn Aspartate and Zn 
Gluconate, I chose to focus on Zn gluconate (ZnG) due to its relationship with clinical 






Figure 3.2  HRV1A and HRV39 ZnG dose-response curves 
 Stocks of HRV1A (A) or HRV39 (B) were incubated with increasing amounts of ZnG as 
indicated in the figure. Virus titers were determined by plaque assay on monolayers of 









Figure 3.3 Effect of Zn 2+ on infectivity of HRVs 14, 16 & 2. 
 Stocks of HRV14 (A), HRV16 (B), and HRV2 (C) were incubated with different 
concentrations of ZnCl or ZnG [mM] as shown in the figures. Virus titers were 




Zn-based inhibition is not universal to picornaviruses 
 
 Given the conservation of both genome and capsid structure among picornavirses, I next 
sought to determine if this inhibition might be a universal, or a more broad characteristic of 
picornaviruses, especially given the previously cited mechanism of Zn-inhibition due to 
disruption of polyprotein processing which was not established to be specific to HRVs (4). 
Experimentation with Poliovirus, Coxsackie B3 virus (CVB3), Endomyocarditis virus (EMCV) 
and Enterovirus 68 (EV68), under identical circumstances with similar and greater quantities of 
ZnG and ZnCl, did not result in a significant decrease in viral titer (Figure 3.4, Figure 3.5 & 
Figure 3.6 ). While the limited scope of other picornaviruses tested does not lend the ability to 
conclusively determine that this inhibition is exclusive HRVs, it does imply that HRVS possess 
an attribute, not conserved across the picornavirus family, that makes them susceptible to 
damage by Zn+ cations. Given that multiple variations in capsid and genome structure exist 
among the picornaviruses tested, investigation into the possible discrepancy lending Zn+ 








Figure 3.4 Effect of ZnG on poliovirus and coxsackievirus (CVB3) 
Stocks of poliovirus (A) and Coxsackievirus B3 (B) were incubated with different concentrations 
of ZnCl or ZnG prior to infection of HeLa cells. Virus titers were determined by plaque assay on 













Figure 3.5 Effect of ZnG on the infectivity of EMCV 
Stocks of EMCV were exposed to ZnG [mM] or left untreated (0) prior to infection of a HeLa 









Figure 3.6 Effect of ZnG on the infectivity of EV68  
Stocks of EV68 were exposed to ZnG [mM] or left untreated (0) prior to inoculation of a HeLa 
cells. Virus titers were determined by plaque assay on monolayers of HeLa cells  
 
Zn-based inhibition of HRVs is not pH dependent 
 
 Given that HRVs hold the distinction of being one of the few acid-labile members of the 
picornavirus family, I next sought to investigate the possible relationship of this inhibition to that 
seen in low pH conditions, and to determine if this Zn-based inhibition of HRVs is pH-
independent. Initial investigation into the pH lability of our HRV1A stocks revealed that a 
significant decrease in titer did not occur until the HRVs were exposed to a pH of 5 or lower, 
despite previous documentation which suggested that a pH of 6.2 or less is capable of rendering 
HRVs non-infectious (4). I then determined that the pH of ZnG-infused viral sera never breached 
a pH level lower than 6.4, even at ZnG concentrations nearly double of what was used to see 
complete HRV1A inhibition (Figure 3.7). Furthermore, even after a decrease in HRV1A titer is 
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seen after exposure to a pH of 5, an additional decline in viral titer is observed after ZnG 
exposure. To determine what, if any, of the inhibition seen with ZnG treatment was attributable 
to aberrations in the ph of the solution, I used zwitterionic (4-(2-hydroxyethly)-1-
piperazineethanesulfonic acid) (HEPES)-buffered ZnG solutions which were confirmed to 
prevent even the slightest fluctuation of pH at the time of viral treatment (Figure 3.8). These 
experiments revealed that no appreciable portion of the inhibition seen is simply a consequence 











Figure 3.7 Effect of pH on HRV1A titer. 
The titer of Untreated HRV1A (0) was compared to that of 8 mM ZnG treated HRV1A and 
HRV1A exposed to a pH of 5 or 3 with and without ZnG. Virus titers were determined by a 












Figure 3.8 Effect of HEPES buffer on ZnG mediated inhibition 
 Stock of HRV1A were untreated, or incubated with 10 mM ZnG, or 10 mM ZnG plus an 
equimolar concentration of HEPES. Virus titers were determined by plaque assay on monolayers 




Zn-based inhibition of HRVs occurs rapidly 
 
 Initial experimentation using the work-flow show in Diagram 3.1 involved incubation of 
HRVs with ZnG for periods of time in excess of 60 minutes as the possible parameters of Zn-
based incubation were uncharacterized, and I had not yet deductively honed in on the optimal 
parameters necessary to observe this inhibition. Having determined the basal quantities and 
conditions necessary to see extracellular Zn-based inhibition of HRVs, I next sought to 
determine if the length of exposure had a significant impact on viral inhibition. Examining the 
results of viral incubation with ZnG for time periods of 5 minutes and 25 minutes revealed that 
the vast majority of viral inhibition occurs in 5 minutes or less, making longer incubation times 
unnecessary (Figure 3.9). While exploration of the degree of inhibition seen at even shorter time 
periods was technically difficult to perform, the profoundly non-linear relationship of duration of 
ZnG exposure and HRV inhibition seen in this assay suggests that inhibition of HRVs occurs 










Figure 3.9 Effect of time on ZnG mediated inhibition  
HRV1A was exposed to 4mM ZnG and 4mM ZnCl for two discrete time periods of 5 min and 25 
min at 37C before infection of HeLa cells. Virus titers were determined by plaque assay on 




Effect of temperature on Zn inhibition  
 
 37C represents the average ambient temperature in most regions of the human body, and 
is therefore physiologically relevant in the context of therapeutic pharmacokinetics. Furthermore, 
this temperature is amenable to HeLa cell growth and survival, and viral infections with 
picornaviruses are traditionally performed at this temperature. Consequently, 37C was chosen as 
the initial temperature parameter when exploring Zn-based HRV inhibition. However, it is noted 
that HRV incubation in plaque assays is optimized at 33-34 C. To determine if temperature 
played any significant role in Zn-based HRV inhibition, identical assays were performed (as in 
Diagram 3.1) with HRV incubation at 4C. While a slight decrease is observed in the 4C 
incubation group compared to the 37C incubation group, this effect is likely due to the well-
established kinetic relationship of molecular movement and Brownian motion in aqueous 
solutions, and allowed me to conclude that Zn-based inhibition of HRVs was not significantly 
dependent upon temperature beyond what would normally be expected due to the universal laws 
of thermodynamics (Figure 3.10). The inability of 4C to substantially dampen this inhibition 










Figure 3.10 Effect of temperature on Zn inhibition  
HRV1A was treated with 4mM ZnG and subjected to 30 min of incubation at 25C and 4C and 
the titers compared to that of untreated (UT) HRV1A. Virus titers were determined by plaque 




2+ cations do not universally inhibit HRVs 
 
 With similar chemical reactivity, 2+ cations often behave analogously in biological 
systems. In some studies, substitution of a Cu ion for a Zn ion has no discernible effect on 
enzymatic function (111). Consequently, I sought to determine if the inhibition I was observing 
was a property exclusive to Zn+, or an effect that can be seen when HRVS are exposed to any 2+ 
cation in abundance. Mg+, Mn+ and Ca+ were investigated for possible Zn-inhibition given their 
favorable biochemical profile for low cytotoxicity in tissue culture cells and ready availability. 
Experiments using Mg2+, Mn2+ and Ca2+ in an experimental workflow identical to that seen 
with Zn inhibition (Diagram 3.1), and at similar and greater concentrations, resulted in no 
discernible inhibition of HRV1A. While issues of cytotoxicity and commercial availability 
prevented a more comprehensive investigation into the effects of all 2+ cations in nature, this 
result implies that a property characteristic, but perhaps not exclusive to Zn2+, is responsible for 
HRV inhibition, and that this inhibition is not due to the general presence of any 2+ cation in 









Figure 3.11 Effect of Mg2+, Mn2+, and Ca2+ on HRV  
Stocks of HRV1A were incubated with different concentrations of MgCl2, MnCl2, or CaCl2 
[mM] as shown in the figure before infection of HeLa cells. Virus titers were determined by 




EDTA Chelation of Zinc 
 
 EDTA (Ethylenediaminetetraacetic acid) has a chemical profile that makes it a well-
established Chelator of metal cations like Zn. Given this Zn-chelating property of EDTA and it’s 
amenability to use in tissue culture, I sought to determine if EDTA chelation of Zn could prevent 
or reverse the Zn-based inhibition of HRV1A. Using both equimolar, 1:2 and 2:1 ratios of ZnG 
to EDTA, I found that exposure of Zn to EDTA could prevent downstream inhibition of 
HRV1A, presumably by chelating Zn out of solution, and thereby prevent its interaction with 
HRV1A (Diagram 3.2, Figure 3.12). However, addition of EDTA at identical and greater ratios 
to Zn-treated HRVs could not reverse the HRV1A inhibition that had already occurred. This 
finding demonstrates that either the Zn mediated damage to HRV1A particles is irreversible, or 
that the Zn - HRV1A interaction is stronger than the chemical pull of Zn - EDTA chelation 













Diagram 3.2 EDTA mixed with Zinc 
EDTA is mixed with Zn prior to treatment of an HRV in isolation. Virus titer is then determined 















Diagram 3.3 Adding EDTA after Zn treatment 
The HRV aliquot is treated sequentially with Zn and EDTA, with EDTA being added only after 
HRV incubation with Zn. After EDTA incubation, virus titer is determined by plaque assays on 












Figure 3.12 EDTA can prevent ZnG inhibition of HRV1A 
Compared to the untreated control (0), the addition of 10 and 20 mM EDTA to 10mM ZnG 
solutions, prior to HRV treatment, can prevent the degree of inhibition seen with ZnG alone. 












Figure 3.13 Effect of EDTA on inhibition of HRV1A infectivity by ZnG  
Stocks of HRV1A were incubated with Zn, ZnG plus EDTA (ZnG + EDTA), or ZnG followed 
by EDTA (ZnG/EDTA) with ratios of 1:2 and 1:4 yielding nearly identical results. Virus titers 












Figure 3.14 Effect of EDTA on inhibition of HRV2 infectivity by ZnG 
Stocks of HRV2 were incubated with (20mM) EDTA alone (E), (10mM) ZnG alone (Zn), or a 
mixture of (1:2) ZnG and EDTA (Zn+E) before HRV2 infection (/RV2), and compared to an 
untreated HRV2 control (0), and the result of Zn exposure to HRV2 in isolation (Zn+RV2) 
followed by EDTA addition (/EDTA) at a ratio of 1:2. Virus titers were determined by plaque 
assays on monolayers of HeLa cells.   
 
Zn-based inhibition does not involve the cell receptor interface 
 
 The virus-cell receptor interaction necessary to trigger endocytosis of virions is a crucial 
step in the viral infectious cycle, and impeding this interaction has been the goal of many 
antiviral therapeutics. To determine if Zn -based inhibition of HRV1A is dependent upon Zn 
activity at the virus-receptor interface, Infectious Center Plaque Assays (ICPAs) were designed. 
In the canonical ICPA assay, virus-infected cells are seeded upon an uninfected cell monolayer, 
leading to the formation of plaques after viral replication and consequential cell lysis of the 
initial virus-infected seed cell and infection of surrounding cells on the monolayer. Therefore, 
plaque formation in an ICPA assay is dependent upon successful viral attachment, internalization 
and replication in the first population of infected cells, the cells that are then seeded atop a 
secondary monolayer. Abrogation of any step in the viral replication cycle in the initially 
infected cell will result in a failure to form plaques after infection of the secondary cell 
monolayer, including initial viral attachment to the receptor of the seed cell. To determine if Zn-
inhibitory activity is dependent upon the availability of the virus-receptor interface, I devised an 
ICPA assay wherein transient Zn exposure occurred after theoretical virus-cell receptor binding, 
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but before virus internalization. Due to prior studies on time dependence, I was able to conclude 
that non-cytotoxic transient exposure would be sufficient to inhibit HRV1A, if such inhibition 
can occur after receptor binding, without putting the health of the cells at risk.  I hypothesized 
that a decrease in plaques after this transient ZnG treatment of virions already theoretically 
bound to the LDLR receptor would indicate that interaction with the virus-cell receptor interface 
was not required for Zn-based inhibition of HRV1A. If access to the virus-cell receptor interface 
was required for Zn+ inhibition, this would result in a failure of ZnG to reduce the number of 
plaques on the secondary cell monolayer when applied after receptor binding of the first 
population of cells has already occurred. Prevention of virion internalization was performed by 
maintaining the virus-cell inoculate at 4C, a condition previously shown to allow receptor 
binding while being highly inhibitory towards the endocytic process (4). Under these conditions, 
HRV1A virions can interact and bind their cognate receptor while remaining on the surface of 
the cell rather than being immediately internalized, and therefore plaques will only be seen on 
the secondary monolayer if the Zn treated HRV was able to remain infectious and attached to the 
receptor on its seeding cell from the first monolayer (Diagram 3.4). A poliovirus control,  and 
plaque assays using the supernatants, were used to confirm that this experimental process was 



















Diagram 3.4 The ICPA assay  
A confluent monolayer of HeLa cells is inoculated with HRV and held at 4C for 30 minutes with 
gentle agitation. The monolayer is transiently exposed to ZnG for 5 min, followed by EDTA to 
chelate excess Zn. After undergoing washes, the cells are mechanically harvested, gently isolated 
via centrifugation and then re-suspended and diluted in PBS and plated upon another confluent 
monolayer of HeLa cells. Plaques resulting from this process are indicative of successful 
attachment of the HRV to its cellular receptor on the first monolayer of cells and sustained 
receptor attachment and infectivity of the HRV after Zn exposure.  
 
 The following figures are the result of an ICPA wherein a monolayer of HeLa cells was 
infected with HRV1A while held at 4C to prevent endocytosis. After sufficient incubation to 
allow viral binding of the receptor, ZnG was added at inhibitory concentrations for 5 min at 4C; 
a duration and temperature that I had previously shown to be amenable to Zn+ inhibition of 
HRVs (Figure 3.15). EDTA was then used to chelate excess Zn from solution, a procedure I had 
previously determined was not capable of reversing Zn-based HRV inhibition (Figure 3.13). 
Following transient ZnG exposure, this monolayer was harvested, gently washed and re-
suspended in ZnG-free PBS, also at 4C. Serial dilutions of the resulting HRV1A- infected HeLa 
cells where then applied to a new HeLa cell monolayer and subjected to identical HRV1A 
plaquing conditions as shown in Diagram 3.1. The resulting decrease in plaques indicates that 
Zn- mediated inhibition of HRV1A was still able to occur after binding of HRV1A to the LDLR 
receptor. This finding demonstrates that disruption of the virus-cell receptor interaction is not 
topographically required for the mechanistic action of Zn-based HRV inhibition, as exclusion of 
Zn from this interface using pre-bound virions resulted in a decrease in plaque formation on parr 
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with that seen in traditional plaque assays. Therefore, the HRV1A - LDLR receptor interaction is 
not likely to play a mechanistic role in the Zn-based inhibition of HRV1A. 
  To eliminate the possibility that Zn treatment in this assay was simply removing 
infectious HRV1A from its receptor, thus preventing down-stream ICPA plaques, the 
Supernatants (SN) from the first inoculation were harvested and also assayed for infectivity and 
comparison to ICPA plaques (Figure 3.15).  This assay was done with 1x and 2x comparative 










Figure 3.15 HRV1A ICPA assay  
The initial inoculate from the first monolayer (SN), cells bound with untreated HRVIA (UT) and 
cells bound and then treated with 8mM ZnG (ZnG) were used in increasing quantities (1x, 2x) to 
infect the second HeLa cell monolayer of the ICPA assay. Virus titers were determined by an 
ICPA assay where plaques are the result of infection by a virus-harboring seed cell from the first 
infected monolayer.   
 
 To control for the efficacy of the ICPA assay, poliovirus (PV), which I previously 
demonstrated to be uninhibited by extracellular Zn compounds (Figure 3.4), was also subjected 
to an ICPA under identical conditions resulting in no decrease in ICPA plaque formation (Figure 
3.16). Furthermore, experimentation with the centrifugal supernatants and coinciding increase in 
plaques seen with 2x addition of inoculate in both the control and treated groups bolsters the 
validity of this experimental procedure, indicating that the increase and decreases in plaque 








Figure 3.16 Poliovirus (PV) ICPA assay 
 Untreated (UT) and 8mM ZnG treated (ZnG) PV inoculated monolayers were seeded onto a 
second monolayer of HeLa cells. Virus titers were determined by an ICPA assay where plaques 
are the result of infection by a virus-harboring seed cells form the first infected monolayer 
 
 To lend credence to the literature-supported, assumption that holding the first HRV - 
inoculated HeLa cell monolayer at 4C effectively prevents endocytosis, the amount of infectious 
center plaques with and without ZnG treatment was observed as a function of time. HRV- 
inoculated monolayers were held at 4C for 20 and 40 min, and the amount of infectious center 
plaques in the second monolayer resulting from harvested cells, and the residual viral supernatant 
from the first infection, were observed. With no significant difference in plaque number seen 
between the 20 and 40 min 4C incubation groups, it is unlikely that duration of time at 4C is able 






Figure 3.17 ICPA and 4C incubation 
The supernatant from the initial monolayer inoculation (SN), untreated HRV1A- cells (UT) and 
8mM ZnG treated HRV1A -cells (ZnT) were used to infect a second HeLa monolayer after 20 or 
40 min incubation at 4C prior to Zn treatment. Virus titers were determined by an ICPA assay 





Zn-treated HRV1A is still able to interact with the LDLR receptor 
 
 HRVs interact with their cellular receptor via contacts on the five-fold axis of the viral 
capsid which is composed of aggregates of viral capsid proteins that form the building blocks of 
the icosahedron (4). Therefore, binding of HRV1A to the LDLR receptor necessitates that the 
repeating protomer units of the viral capsid remain intact for the topography-dependent 
interaction with the cellular receptor to occur. To determine if Zn disrupts the non-covalent 
interaction that maintains these promoter units, I devised a competition-based assay wherein Zn-
treated HRV1A was tested for the ability to interact with the LDLR receptor. Because Zn-treated 
HRV1A does not result in a successful infectious cycle and therefore does not result in plaque 
formation, I hypothesized that increasing quantities of Zn-treated HRV1A mixed in solution with 
a constant amount of untreated HRV1A would result in a decrease in total plaques observed if 
the Zn-treated HRV1A are capable of occupying the finite number LDLR binding sites within 
the HeLa cell monolayer (Diagram 3.5). EDTA was used to remove excess Zn from solution to 
prevent inactivation of the untreated HRV1A after my prior experimentation demonstrated it’s 












Diagram 3.5 The competition assay 
Holding the amount of untreated, infectious HRV capable of plaques constant, uninfectious Zn 
treated HRV is titrated into aliquots of untreated HRV after chelation of excess Zn using EDTA. 
The untreated and Zn-treated virus mixture is then used to inoculate a confluent monolayer of 
HeLa cells at an MOI > 15. Plaques were visualized after application of a semi-solid agarose 
overlay, incubation, cell fixation and crystal violet staining. A decrease in plaques is indicative 
of un-infectious HRV competing with infectious HRV for receptor binding sites.   
 
 The results of this assay demonstrated that Zn-treated HRV1A is still able to interact with 
the LDLR receptor, leading to a decrease in the number of untreated, infectious HRV1A that can 
bind a receptor to gain cell entry, and hence a decrease in the number of plaques formed as 
increasing amounts of Zn-treated HRV1A are titrated into the mixture. This finding implies that 
Zn does not sufficiently disrupt the viral capsid, specifically at the 5-fold axis, allowing Zn 
inactivated HRV1A to occupy the limited supply of LDLR binding sites, despite its inability to 









Figure 3.18 Effect of Zn+-treated HRV on virus binding to cells 
Increasing amounts of Zn-inactivated HRV1A (A) or UV-inactivated HRV1A (B) were mixed 
with a fixed amount of untreated HRV1A and given access to bind to the LDLR receptor. After 
washing, the number of bound virus particles was determined by plaque assay on monolayers of 




 To control for the validity of this assay, UV-inactivated HRV1A was used as a control. 
UV-light damage to viral RNA, and the resulting abrogation of infectivity is well documented 
(4). This viral RNA damage occurs while presumably leaving the viral capsid largely intact. 
After determining the conditions under which 100% inactivation of HRV1A could be achieved 
(Figure 3.19), this process was used to make an inactivated HRV1A control that demonstrated 
the efficacy of this assay. The possible variation in competitive ability of some UV-treated 
HRV1A aliquots is presumably due to the possible damage to the viral capsid proteins that may 









Figure 3.19 Effect of UV-treatment on HRV1A infectivity 
Stocks of HRV1A were spread into a thin-aqueous layer on a 10cm petri plate and subjected to 
increasing amounts of UV light. Virus titer was determined by plaque assay on a monolayer of 
HeLa cells.  
 
HRV1A capsid proteins do not appear altered after Zn 
 
 Without heat and reducing agents to completely eliminate protein to protein interaction 
and tertiary structure, native gels allow for the visualization and characterization of protein 
complexes as they migrate through a porous matrix. The metastability of the viral capsid 
necessitates the use of non-ionic bonds to aggregate the individual viral proteins into repeating 
protomers that comprise the complete capsid (Diagram 3.6). To investigate the stability of these 
non-ionic associations between viral capsid proteins and protomers, Zn treated and untreated 
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sucrose gradient purified HRV1A were subjected to native protein gel analysis using a variety of 
conditions in an attempt to preserve natural capsid protein interactions. Using both coomassie-
blue and silver stain, the migration of the viral capsid proteins and their interaction after ZnG 
treatment could be visualized. While the unavailability of HRV1A - specific antibodies 
precluded the positive identification of each protein complex, the seemingly identical migration 
of viral capsid proteins in the untreated and ZnG treated groups as visualized with a sensitive 
silver-staining procedure, suggests that Zn+ treatment does not profoundly disrupt the interaction 
of viral capsid proteins at a level that can be observed using native gel electrophoresis. This 
result bolsters the conclusion of the Zn-treated HRV1A competition assay that indicates that the 
Zn-treated capsid must remain intact, at least at the protomer level, to successfully compete with 
untreated HRV1A for LDLR binding sites (Figure 3.20) Because smaller molecular weight 
products cannot be seen in the Zn-treated lanes as one would expect if polypeptide interactions 
were being disrupted to result in smaller aggregates, the dampening of signal in Zn-treated lanes 
is most likely due to the interaction of Zn in the sample with the Silver stain. Notably, while not 
shown here, the coomassie stained gels did not exhibit this decrease in band darkness in the Zn-
treated lanes, supporting the notoin that the band signal is predicated on the interaction of Zn in 
the sample with the staining agent. While less sensitive, the coomassie stained gels also revealed 




















Figure 3.20 HRV1A native gel after Zn treatment. 
 Sucrose Gradient HRV1A from two different, but theoretically equivalent fractions, were 
subjected to Native Gel electrophoresis for the conditions given (12% Native PAGE, 4C, 150V, 
1hr) with and without 8mM ZnCl (Zn) treatment, and with Pyrithione (Pyr) treatment alone or in 
conjunction with ZnG (Zn —> Pyr). A Native gel marker on the left most lane gives an 
approximate indication of protein complex size. A non-specific Silver Staining protocol was 
used to visualize all proteins, viral and non-viral, in the original sample. The viral structure 












Diagram 3.6 The 475 kDa Pentamer of HRV1A 
The HRV1A capsid is composed of 4 proteins whose formation of repeating units results in the 
formation of the holistic viral capsid. A principle unit of this structure on which receptor-binding 
interactions takes place is the viral protomer, composed of 5 of each of the viral capsid proteins. 
VP4 resides internal to the capsid structure and is not shown in the diagram.  
 
Primary HRV1A viral proteins are not altered by Zn treatment  
   
Previous studies investigating an anti-picornaviral mechanism of Zn activity observed disruption 
and possibly modulation of the picornaviral polyprotein in the presence of high intracellular 
concentrations of Zn. To determine if Zn might have a likewise detrimental effect on the capsid 
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proteins that originated from the polyprotein, I sought to visualize viral capsid proteins with and 
without Zn treatment to rule out possible Zn- mitigated damage that might cause visible cleavage 
or dissolution. Denaturing PAGE analysis with coomassie-blue (not shown) and silver-staining 
of sucrose gradient purified untreated and ZnG treated HRV1A revealed that untreated and ZnG 
treated HRV1A capsid proteins can be found to sediment in the same sucrose gradient fractions, 
bolstering prior observations which indicate that degradation of viral proteins is not the 
mechanism of extracellular Zn inhibition of HRVs. Without the availability of an HRV1A- 
specific antibody for each viral protein, the positive identification of each viral protein could not 
be made. However, the totality of the uniform lack of change seen between the untreated and Zn 












Figure 3.21 SDS-PAGE does not reveal Zn-mediated capsid protein degradation.  
Untreated (U) and 5mM and 10mM Zn Chloride treated (ZnCl) aliquots of sucrose gradient 
purified HRV1A were subjected to 12% SDS PAGE at approximate 90-120V for 1-1.5 hrs. A 
standard protein size marker is shown in the right-most lane of the figure.   









The presence of sucrose can prevent Zn-mediated inhibition of HRVIA  
 
 While experimenting with sucrose gradient purified HRV1A, a decrease in the 
degree inhibition was observed when direct aliquots of sucrose gradient purified HRV1A 
were subjected to Zn treatment. However, after dialysis to remove the sucrose from the 
purified viral fraction, Zn sensitivity was restored (data not shown). Consultation with 
literature implied that the chemical make-up of sucrose could lend it the ability to chelate 
2+ cations . This potential finding is interesting given the historical use of sucrose and 
related sugars used in Zn lozenges in an effort to make them more palatable, and thereby 
increase trial enrollee compliance. Directly assaying non-sucrose exposed stocks of 
HRV1A sera for Zn sensitivity in conjunction with sucrose-purified HRV1A in which the 
sucrose had not been dialyzed from the sample, reinforced this finding. A lower titer 
sucrose gradient purified fraction of HRV1A was used for this investigation in an effort 
to conserve higher-titer sucrose gradient purified fractions for more critical experiments 























Figure 3.23  Sucrose dampens Zn inhibition of HRV1A. 
 Untreated (UT) and Zn Gluconate treated (ZnG) treated HRV1A with without the presence of 
approximate 30% sucrose were compared. Viral titers were determined by plaque assay on a 




RNA analysis of Zn-treated HRV1A 
 
 The HRV infectious cycle necessitates that the viral RNA genome be delivered to 
the cell cytoplasm intact. Prior studies with cesium have indicated that the capsid 
structure of HRVs is more permeable than that of PV (4). I sought to determine if Zn 
treatment resulted in damage to the HRV1A genome through possible Zn-penetration of 
the viral capsid structure, or Zn mediated partial-dissolution of the capsid structure which 
might make viral RNA susceptible to Rnases. Aliquots of centrifugation-purified HRV1A 
were subjected to Zn treatment, followed by incubation with Rnase 1 whose activity is 
not hindered by the presence of metal cations. RNA was isolated via Trizol extraction 
and resuspended in Rnase-free water prior to inspection. The amount of untreated RNA 
detected decreased dramatically after Rnase 1 exposure. While the total amount of RNA 
in the Zn-treated group was significantly less than that seen in the untreated Rnase-free 
fraction, the decrease in RNA present after Rnase1 exposure did not vary as greatly for 
the Zn-treated groups (Figure 3.23). This experiment revealed that less total RNA can be 
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found after Zn-treatment, and that remaining RNA might be less susceptible to the 
activity of RNAse 1. Alternatively, while RNAse 1 is alleged to be impervious to the 
presence of metal cations, it is possible that the Zn in solution hindered its catalytic 










Figure 3.23 Total RNA after Zn Treatment and effect of exposure to Rnase1.  
100 ul aliquots of untreated and 10 mM ZnG treated HRV1A was exposed to 100 units of Rnase 
for 5 to 10 minutes prior to Trizol extraction and examination using a spectrophotometer to assay 
for total RNA. 
 
Decreased quantities of HRV1A RNA after Zn treatment 
 
 Centrifugation of virus particles on a sucrose gradient, wherein they settle 
according to their buoyant density, is a common means of purification of virus particles, 
separating the virions from other components of the sera milieu. During centrifugation, 
HRV1A characteristically sediments in sucrose gradient fractions that correspond to 
approximately 30-35% sucrose (w/v). Through careful fractionation of the sucrose 
gradient column, aliquots of highly purified and concentrated virus can be obtained. The 
presence and amount of infectious virus in each fraction can be determined by plaque 
assay. Sucrose gradient centrifugation of untreated and Zn-treated HRV1A, followed by a 
downstream plaque assay to determine the amount of virus in each fraction, or every 
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other fraction, was performed. The resulting curve demonstrated the fractions with peak 
infectivity, as well as the predictable absence of infectious virus in abundance in the 
corresponding Zn-treated sucrose fractions. While initially just used as a method to 
obtain purified virus for other experiments, to probe for the presence of viral RNA in 
these fractions, 250 ul aliquots from each fraction were subjected to Trizol extraction, 
reverse transcription using random hexamers and then PCR using HRV1A-specific 
primers . The resulting PCR product was visualized on an ethidium bromide (ETBR) 
agarose gel (Figure 3.24 B). This process was performed on the fractions of peak 
infectivity of the both the untreated and Zn-treated sucrose gradient centrifugation- 
purified sample sets, as well as every other fraction in higher and lower fractions in the 
Zn treated group to probe for possible sedimentation differences. Subject to identical 
extraction and PCR conditions, this result indicates that while less HRV1A genomic 
RNA is detected, the RNA is present in the same fractions as that seen with untreated 
HRV1A RNA. This nearly identical RNA sedimentation profile implies that Zn-treated 
RNA sediments in same fractions as RNA whose capsid structure had not been subject to 
Zn-onslaught. Given the relationship between molecular weight of a structure and its 
sedimentation profile, this result implies that the remaining RNA detected was within or 
associated with a whole or partial viral capsid structure, like that of untreated RNA. This 
result bolsters the notion that the viral capsid structure is not severely disrupted by Zn 
exposure and that Zn-treatment facilitates the degradation of viral RNA. However, it is 
also possible that the vestige of RNA observed here is merely that belonging to virus 






Figure 3.24 Sucrose gradient analysis of HRV after Zn+ treatment   
Approximately 2 x 10 ^8 PFU of HRV1A were either untreated, or incubated with 10 mM ZnG, 
and then fractionated on a 5-45% (w/v) sucrose gradient. Infectivity in each fraction was 
determined by plaque assay on monolayers of HeLa cells. The gradient shown in (A) is from 
untreated HRV1A (purple) and Zn-treated HRVIA (green). Viral RNA in sucrose gradient 
fractions was assayed by gel electrophoresis (B) after reverse-transcription and PCR with 
HRV1A-specific primers. UT, untreated; ZT, ZnG treated. Titers in each fraction were 
determined by plaque assay on monolayers of Hela cells. 
 
Northern blot visualization of HRV1A RNA 
 
 To visualize the impact of ZnG treatment on HRV1A genomic RNA, Northern Blot 
analysis using an HRV1A - specific digoxigenin probe was conducted. The HRV1A digoxigenin 
probe was synthesized using combinations of the HRV1A- primers and random hexamers in 
combination with an HRV1A DNA template. After subjection to agarose gel electrophoresis, the 
viral and control RNA synthesized using T7 polymerase and the pACYC177-Xmal-T7-WT-
RV1A-Xho1 plasmid were transferred onto a positively charged membrane and probed for the 
presence of viral RNA. In addition to disappearance of full-length HRV1A genomic RNA as 
compared to the synthetic control (Figure 3.25), northern blot analysis using different conditions 
and probes of different lengths consistently revealed that ZnG treated HRV1A resulted in lower 
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molecular weight RNA binding targets, and a visible general decrease in signal. Furthermore, 
extensive Rnase inhibition prior to Zn treatment or no treatment, demonstrates that his 
degradation cannot be attributable to possible Rnases that might have contaminated the 
experimental process despite usage of DepC water and cleansing of the workspace and 
experimental tools with RNAse away (Figure 2.1.15.2). Given the differential migration pattern 
of ZnG treated HRV1A RNA, or its absence all together, the aggregate result of these northern 
blots suggests that ZnG treatment of HRV1A results in degradation of viral genomic RNA 








Figure 3.25 Northern blot hybridization of full-length genome.  
Approximately 1 x 10 ^7 PFU of HRV1A were either untreated (2) or ZnG treated (5) and 
compared to a full-length synthetic RNA clone generated using T7 polymerase and PACY1A  
plasmid (1) after being probed with a ~ 500bp  HRV1A specific digoxigenin labeled probe. 










Figure 3.26  Northern blot hybridization analysis of RNA (1) 
Approximately 4 x 10^6 PFU of HRV1A were either untreated, or incubated with 10 mM ZnG, 
and then viral RNA was extracted, fractionated by agarose gel electrophoresis, and transferred to 
a membrane for hybridization with a HRV specific DNA probe. C, cellular RNA; U, viral RNA 
from untreated sample; U+R, viral RNA from untreated sample in the presence of RNAsin; Z, 















Figure 3.27  Northern blot hybridization of RNA (2)  
Approximately 6 x 10 ^5 PFU or HRV1A were treated with 10mM Zn (ZT) or left untreated 
(UT), and then the viral RNA was extracted using Trizol, fractionated by gel electrophoresis and 
then transferred to a nylon membrane and probed using a digoxigenin probe made with random 




Zn resistant HRV1A phenotype 
 
 To determine the attributes of HRV1A that make it susceptible to inhibition with Zn 
compounds, I decided to cultivate and characterize Zn-resistant HRV1A for comparison. Due to 
the lack of a proof-reading mechanism, the RNA polymerase of picornaviruses is highly error 
prone, producing considerable genetic diversity within the populations (75). This creation of 
genetic heterogeneity within the HRV1A population results in both a high probability of drug-
resistant HRV1A selection, and also necessitates the isolation of a single progenitor virion to 
prevent heterogeneity within the viral population that might make the establishment of a 
consensus sequence that is representative of the “average’ genome impossible. While single-
plaque purification of surviving HRV1A after ZnG treatment was unsuccessful due to the 
insufficient number of virus particles for downstream passages and sequencing, an analogous 
scheme for mutant isolation was devised which proved to be more successful at isolation of Zn-
resistant mutants in quantities amenable to downstream passages. A marked decrease in viral 
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fitness was evident with sustained lower-titer in Zn-resistant populations as well as a variable 
plaque phenotype that features mostly small, anemic plaques compared to wild-type HRV1A 








Figure 3.28 Plaque phenotype of Zn-resistant HRV.  
Plaques formed by wild type HRV1A (A) or Zn-Resistant HRV1A (B) after 96 hr on confluent 
monolayers of HeLa cells.		
	
Zn-resistant HRV1A isolation 
 
 As an alternative to the single-plaque isolation strategy, an alternative process illustrated 
in Diagram 3.6 was devised which relied on serial dilutions and CPE detection on a massive 
scale. In doing so, 6 HRV1A mutants were identified that demonstrated an increased resistance 
to inhibition by Zn compared to their wild-type counterparts, and existed in sufficient quantities 
that made them amenable to downstream sequencing analysis as well as having a strong 
consensus sequence that could be used for genotyping. However, the titers of these viral stocks 
were typically ~100 fold lower or more than wild type virus and retained a small plaque 
phenotype despite numerous passages. These observations, coupled with the general scarcity of 
mutant populations after ZnG treatment, emphasizes that resistance to Zn+ decreases the overall 



















Diagram 3.6 Isolation of Zn-resistant HRV1A   
Samples of Zn treated HRV1A were treated with EDTA to removed excess Zn, serially diluted 
and used to inoculate confluent monolayers of HeLa cells in a 24 well plate format. After 4-5 
days of incubation, the supernatant of each well was harvested and each of the 24 wells were 
fixed and then stained with crystal violet to visualize the HeLa monolayer and detect viral CPE. 
The supernatant from wells in dilution sets wherein little to no CPE occurred, and could 
therefore plausibly be from a single virus progenitor, underwent serial passages of HeLa grow-up 
and Zn - treatment. 
 
Figure 3.29 HRV1A mutants resistant to inhibition by Zn.  
Stocks of wild type HRV1 (wt) or six mutants selected for resistance to Zn+ (mut 1-6) were 
incubated with ZnG (Z). All mutant viruses were incubated with 10 mM ZnG except for #2 
which was incubated with 2 mM ZnG. Virus titers were determined by plaque assay on 







Mutations found in Zn-resistant isolates  
 
 The genetic analysis of the HRV2A Zn-resistant isolates was performed using primers I 
designed for HRV1A. The genome of each of the 6 mutants was analyzed after RNA extraction 
and PCR amplification of each region. Additional mutants that demonstrated Zn-resistant were 
similarly isolated, but a homogenous consensus genome sequences could not be generated. 
Alignment of genome sequences with that of wild-type, Zn+-susceptible HRV1A revealed 3 
distinct mutations in multiple isolates, both alone and in combination (Figure 3.31). These 
mutations were not seen in any of the wild-type control isolates that were sequenced. All three 
point mutations lead to amino acid changes in viral capsid protein VP1. Two changes, at residues 
87 and 91, are located on the B-C loop, which forms a major antigenic region on the capsid 
surface. In addition, a change was identified in some isolates from Asn to Lys at residue 29 of 




Figure 3.30  Mutations found in Zn-resistant HRV1A 
 Amino acid changes at VP1 residues 29, 87, and 91 are shown in the context of a protomer (A), 
on the surface of the full capsid (B), and on the capsid interior (C). Color key: VP1 (blue), VP2 
(yellow), VP3 (red), VP4 (green). On the capsid surface amino acid 87 is shown in hot pink 
spheres, and amino acid 91 is colored cyan. On the capsid interior amino acid 29 is shown as 
grey spheres. Images were produced using MacPymol with PDB file 1r1a.pdb. Full and half 


















Figure 3.31 Summation of Zn-resistant mutant findings  
Residues diverging from that seen in wild-type HRV1A are demarked with a gray background. 
 
 
Cloning and transfection of mutant HRV1A 
 
 Using the pACY177-Xmal-T7-WT-RV1A plasmid (Diagram 3.9), site directed 
mutagenesis was performed using mutagenesis sequencing primers corresponding to the VP1 
region (see Materials and Methods). A diagram of the cloning scheme is shown below (Diagram 
3.7 and Diagram 3.8). Confirmation of the singular successful incorporation of each mutation 
was determined through sequencing. Using T7 polymerase, full length RNA transcripts of each 
mutant virus clone were generated and used for transfection using 3 different lipofectamine- 
based procedures and H1- HeLa cells. While confirmation of successful transfection of each 
clone was performed, and some CPE resulted from passages of these viruses, their titer remained 
critically low, making downstream characterization impossible. Removal of Zn pressure did not 




Diagram 3.7 Cloning strategy 
Each of the three mutations discovered in Zn-resistant isolates were separately introduced into 
the pACY177-Xmal-T7-WT-RV1A plasmid using a procedure that utilized 4 primers, 2 of 
which were custom-designed to contain the point mutation desired. The primers used for this 
process and a detailed procedural description can be found in the material and methods section.  





Diagram 3.8 Overlapping HRV1A primers  
Overlapping primers, each yielding a 500-600 amplicon were designed to fully-cover the 
HRV1A genome. The Tm of each primer was kept in a range that allow them to be used 



















Diagram 3.9 The pACYC177-Xmal-T7-WT-RV1A-Xho1 plasmid 
The pACYC177-Xmal-T7-WT-RV1A-Xho1 plasmid contains the full-length HRV1A genome as 
well as other features such as a T7 promoter site for full-length viral RNA synthesis. This and 
additional relevant features, such as the cut-sites for Sfo1 and Sac, which were used to excise and 




























Previous studies with picornaviruses and ionophores hinokital (HK) and pyrithione  (PT) 
focused upon their potential antiviral utility in an intracellular environment. These studies found 
that in conjunction with Zn, these ionophores could impede intracellular steps in the picornaviral 
infectious cycle through inhibition of the picornaviral 2A protease and polyprotein processing. 
They further reported that “early stages” of virus infection were unaffected by these compounds. 
Using an approach analogous to that used with Zn compounds alone, I sought to determine the 
outcome of extracellular exposure of HRVs to these ionophores with and without the addition of 
Zn.  
Extracellular exposure of HRVs to PT & HK with Zn 
  
 Extracellular exposure to HK or PT alone, at concentrations where intracellular inhibition 
was documented and at which extracellular Zn exposure is very inhibitory, did not decrease the 
titer of HRV1A . Interestingly, addition of these compounds in conjunction with ZnG lead to 
significant decreases in HRV1A titer, even when the amount of ZnG added was below the 
typical threshold wherein dramatic inhibition with Zn alone is observed (117). The decrease seen 
with HK and ZnG was more dramatic than that of PT and ZnG, however, the addition of 
Hinokital to viral serum led to the immediate formation of a dense visible precipitate whose 
exact chemical or biological composition could not be determined (Figure 4.1). Dissolution of 
HK in solutions with DMSO did not affect downstream precipitate formation. Concern that this 
precipitate may be preventing HRV1A infection by simply occluding receptor binding or 
aggregating viral particles led me to discontinue this line of experimentation as I feared that such 















Figure 4.1 Effect of HK and PT on HRV1A 
 Increasing amounts of [mM] HK and PT in isolation and with 5mM ZnCl (+HK, +PT) were 
used to treat HRV1A and compared to untreated control HRV1A (0) 
 
 Experimentation with major group HRV16 mirrored the results seen with HRV1A. 
Dramatic inhibition was seen with the HK and ZnG precipitate, and HRV16 demonstrated 
sensitivity to PT-ZnG mixtures, even when the amount of ZnG used was below the threshold 
where Zn-based inhibition usually occurs (Figure 4.2). Unfortunately, experimentation with 
HRV39, another major group HRV, was less conclusive for PT and Zn sensitivity, but inhibition 












Figure 4.2  Effects of HK and PT on HRV16  
20mM HK and PT were used to treat HRV16 with and without the addition of 5mM ZnG (Zn) 
and were compared to the untreated (0) and just Zn treated control groups. Virus titers were 


















Figure 4.3 Effects of HK and PT on HRV39 
 20mM HK and PT were used to treat HRV39 with and without the addition of 5mM ZnG (Zn) 
and were compared to the untreated (0) and just Zn treated control groups. Virus titers were 
determined by plaque assay on monolayes of HeLa cells. 
  
  
Poliovirus is not inhibited by HK or PT 
 
 Poliovirus experienced no appreciable inhibition with exposure to HK alone or in 
conjunction with Zn, despite formation of precipitate upon HK addition to viral serum which 
indicates that inhibition due to this compound is not due to universal steric hindrance to all viral - 
cellulr interactions. PV viral titer was also not reduced in the presence of PT or ZnG-PT 
mixtures. Furthermore, neither the ratio, the sequence,  or order of exposure (mixing HK or PT 
with ZnG before PV exposure, or vice-versa) resulted in any decrease in PV titer. This 
observation suggests that Zn-mitigated inhibition with these compounds may also be due to an 

















Figure 4.4 Effect of HK and PT on PV.  
20mM HK and PT were used to treat PV alone or in conjunction with 10mM ZnG (+ZnG) and 
were compared to an untreated control (0). Virus titers were determined by plaque assay on 
monolayes of HeLa cells. 
 
The ratio of PT to Zn modulates the inhibitory outcome 
 
Interestingly, differences in ratio and sequence of exposure was observed to play a 
decisive role in PT & ZnG inhibition of HRV1A. The most profound inhibition of HRV1A 
occurred when Zn exposure occurred first, followed by the addition of PT, and the level of 
inhibition was substantially greater at a Zn to PT ratio of 1:2 as opposed to 1:1 or 1:3. In all 
instances, the degree of inhibition seen was vastly greater than that which was seen with ZnG 
exposure alone. Given that Zn2+ can interact with two PT molecules, this consistent ratio-based 
observation is not unprecedented, and suggests that 2 PT molecules binding the Zn cation plays 
an augmenting role in Zn-based inhibition of HRVs, or facilitates a new, more potent, 




















Figure 4.5  Addition of PT after ZnG treatment 
HRV1A stocks were incubated for 5 min with 5uM ZnG and then PT was added in ratios 1:1, 1:2 
and 1:3. These treatment groups were compared to an untreated (0) and ZnG (5um) only group 
prepared at equal volume under identical conditions. These mixtures were then used to inoculate 
a monolayer of HeLa cells and infectious titer was determined using a plaque assay. 
 
 On the other hand, when HRV1A was first exposed to PT, followed by the addition of 
ZnG, with the ZnG to PT ratios of 1:2 and 1:3, the viral titer of HRV1A was “rescued” or a 
decrease in HRV1A titer was prevented, presumably through protective chelation of Zn ions out 
of solution. A ZnG to PT ratio of 1:1 was unable to prevent inhibition and the decrease in titer 







Figure 4.6  Addition of Zn after PT treatment  
HRV1A stocks were incubated for 20 min with 5uM PT and then ZnG was added to achieve 
ZnG to PT ratios of 1:1, 1:2 and 1:3. These treatment groups were compared to an untreated (0) 
and ZnG (5um) only group prepared at equal volume under identical conditions. These mixtures 
were then used to inoculated a monolayer of HeLa cells and infectious titer was determined 




 Likewise, when PT and ZnG are incubated together at ZnG to PT ratios of 1:2 or 1:3 
prior to HRV1A treatment, the presence of PT seems to have a protective effect, preventing Zn-
based HRV1A inhibition, similar to the relationship between EDTA and PT. 1:1 mixtures of 
ZnG and PT incubated prior to HRV1A treatment resulted in a decrease in viral titer that was 










Figure 4.7 Mixing ZnG and PT prior to HRV1A exposure  
HRV1A stocks were exposed to mixtures of ZnG (5mM) and PT which had undergone 
incubation with each other at ratios of 1:1, 1:2 and 1:3 for 20 min with gentle agitation at room 
temperature. These treatment groups were compared to an untreated (0) and ZnG (5um) only 
group prepared at equal volume under identical conditions. These mixtures were then used to 
inoculate a monolayer of HeLa cells and infectious titer was determined using a plaque assay.  
 
 Taken together, these experiments indicate that Zn antiviral activity is precluded by 
chelation with two PT molecules resulting in steric hindrance or chemical repulsion, or both, 
thereby preventing Zn’s mechanism of action. However, studies with ZnG and PT at ratios of 1:1 
and 1:3 suggests that Zn bound to one PT molecule may actually enhance this antiviral activity, 
given that a 1:1 addition lead to at least a mild increase in HRV1A inhibition compared to Zn 
alone, and 1:3 ratios of Zn and PT consistently exhibited a decrease in protective effect or titer 




Zn-resistant HRV1A mutants and PT 
 
 If the mechanism of inhibition of HRV1A observed with PT in conjunction with ZnG is 
highly similar or identical to that of Zn, Zn-resistant mutants might be expected to be resistant to 
this form of inhibition as well. 3 mutant isolates of unknown genotype were tested which all had 
demonstrated sufficient titer and decreased susceptibility to Zn in comparison to wild-type 
HRV1A. These 3 mutants were subjected to Zn treatment and Zn treatment followed by PT 
exposure. While the mutants did demonstrate a significant degree of resistance to both Zn and Zn 
/ PT exposure, attempts to sequence these mutant populations was stymied due to non-
homogenous sequences with which a consensus strand could not be generated. However, further 









Figure 4.8 PT and ZnG-resistant mutants  
Wild-type (wt) HRV1A stocks and HRV1A that was serially passaged 3-6 times after ZnG 
exposure and had demonstrated some degree of ZnG resistance (mut1, mut2, mut3) were 
subjected to (5mM) ZnG treatment followed by PT (10mM). These HRV1A treatment groups 
were compared to both an untreated mutant control (0) and wild-type controls that had been 
subjected to the same treatments under identical conditions. These mixtures were then used to 






A PDTC-Zn compound is inhibitory to HRV1A 
 
 The potential antiviral activity of Pyrrolidine Dithiocarbamate (PDTC) during 
intracellular stages of the picornaviral infectious cycle has been investigated, and while its 
precise mechanism is unknown, the presence of a 2+ cation such as Zn or Cu was determined to 
be essential for its intracellular viral-replication suppression activity (111). Experiments with 
extracellular PDTC alone, without supplementation of  Zn or Cu, did not result in HRV 
inhibition (Figure 4.9). While this study established that a 2+ cation was essential for PDTC 
antiviral activity during intracellular stages of the HRV infectious cycle, they did not conduct, or 
did not report, findings for experimentation with extracellular PDTC treatment and 2+ cation 
supplementation.  
 Based upon these prior studies, I sought to determine if PDTC supplemented with Zn 
could be inhibitory to HRVs via extracellular exposure alone. Using concentrations of PDTC 
found to be inhibitory for intracellular processes of HRV infection, I determined that only the 
isolated compound formed by PDTC interaction with Zn could enact extracellular inhibition on 
HRV1A. PDTC alone, and ZnG used at low levels, were previously not documented to be 
capable of HRV inhibition, and likewise, I found that they were not capable of lowering the titer 
of HRV1A in my experiments. Furthermore, sequential exposure of these concentrations of 
PDTC and Zn to extracellular HRV1A did not result in an appreciable decrease in viral titer. 
Only when the precipitate formed by PDTC and Zn after incubation at 37C or higher for at least 
20 minutes was harvested, re-suspended in PBS or water, then used to treat HRV1A, dramatic 
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reduction in viral titer was observed (Figure 4.9). Investigation into the precise parameters 








Figure 4.9 PDTC and HRV1A   
30um Zn and 30umPDTC were used to treat HRV1A in isolation as well as Zn and then PDTC 
(Zn/PDTC) and PDTC then Zn sequentially (PDTC/Zn). Compounds generated via heated 
incubation of PDTC and ZnCl (PDTC + Zn) were shown to decrease the titer of HRV1A at 
approximately a 30uM concentration. Incubations took place at 37C with constant agitation. 
These mixtures were then used to inoculate a monolayer of HeLa cells and infectious titer was 
determined using a plaque assay. 
 
This experimental result indicates that only the stable product of PDTC and Zn is capable 
of extracellular HRV1A inhibition. PDTC and Zn alone at these concentrations, or added in 
succession of each other, or added nearly simultaneously to solutions of HRV, are unable to 
render a decrease in viral titer. While chemical investigation into the precise formula of this 
precipitate has not been performed, prior chemical research on PDTC has concluded that it can 
form complexes, with Zn to PDTC ratios of 1:2. This PDTC-Zn compound has not been 
exhaustively characterized and other studies on its potential antiviral activity have not been 
conducted or reported. However, it’s ability to effect antiviral activity at Zn concentrations 10-
fold less concentrated than that seen with Zn alone, in combination with its documented non-
toxic amenability towards medical use, should make this compound and its derivatives a 
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conceivably profitable area of study. While ZnG was also used in an identical set of experiments, 
I found that formation of the inhibitory precipitate appeared to be optimized with ZnCL, and 
ZnCl was used to supplement PDTC in studies looking at intracellular-based inhibition of HRVs 
and other viruses (Figure 4.10 and Figure 4.11). Unfortunately, testing the inhibitory potential of 
this compound was not performed on other picornaviruses, but I would advocate that doing so 
would potentially be a compelling area of future research, especially given that intracellular 
PDTC-based inhibition was shown to occur with other members of the picornavirus family in 















Figure 4.10  PDTC and EV68.  
EV68 was treated with 30um of the Zn-PDTC compound, PDTC (PDTC) alone or Zn (Zn) 
alone, and compared to a untreated control (0). Incubations took place at 37C with constant 
agitation. These mixtures were then used to inoculated a monolayer of HeLa cells and infectious 




























Figure 4.11  PDTC and PV 
PV was treated with 30um of the Zn-PDTC compound, PDTC (PDTC) alone or Zn (Zn) alone, 
and compared to a untreated control (0). Incubations took place at 37C with constant agitation. 
These mixtures were then used to inoculate a monolayer of HeLa cells and infectious titer was 
determined using a plaque assay. 













Overview and Relevance of Findings 
   
 Previous studies on the mechanism of Zn+ inhibition of HRV infections were 
focused on events within infected cells that occur after viral entry (4). The results of these 
studies suggested that an intracellular interaction between Zn and the nascent capsid 
polyproteins might impede the HRV infectious cycle and account for successes seen in 
some Zn-therapeutic clinical trials. However, the cytotoxic concentrations of Zn 
necessary to observe this effect make it unlikely that this is the central mechanism of 
action, especially in the physiological context of lozenge or nasal spray use, where Zn 
cations would not only have to forcibly traverse the cellular plasma membrane, but also 
pass through protective secretions characteristic of the naso-pharyngel mucosal 
environment, making the bio-availability of Zn in doubt (119). Consequently, while 
intracellularly introduced Zn may, indeed, interrupt HRV polyprotein processing, the 
notion that this activity could single-handedly account for the degree of HRV inhibition 
necessary to yield a therapeutic benefit is unlikely. In the 1976 study led by Korant, 
wherein Zn based disruption and association with the nascent HRV polypeptide was 
observed, no other picornaviruses were investigated, making the HRV-specificity of this 
mechanism undetermined (106). Furthermore, in the 1974 findings by Butterworth, on 
which the aforementioned research was based, accumulation of nascent polypeptide 
precursors after a transient increase in intracellular Zn, was observed in HRV1A, PV and 
EMCV, with the latter two picornaviruses having never been documented to experience 
Zn-inhibition like that seen with HRVs (4). In addition, the Zn-based inhibition of 
polyprotein processing was demonstrated to be reversible, a key characteristic that 
differentiates this mechanism from the seemingly irreversible one investigated here (4). 
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Taken together, these observations imply that the inhibitory Zn interaction with the 
picornaviral polypeptide precursor documented in these prior two studies is not likely to 
be responsible for the very HRV-specific inhibition discussed here, and reported in prior 
investigations.   
 Here I have shown that extracellular exposure of HRVs to Zn, prior to contact 
with a susceptible and permissive cell, is sufficient to reduce viral infectivity. This 
inhibition might account for the reduction in duration and severity of symptoms of the 
common cold reported in some clinical trials in which Zn+ is provided via a lozenge or 
nasal-spray conduit (120).Transient exposure of extracellular virions to Zn within the 
respiratory tract could theoretically reduce viral infectivity, preventing infection of 
nearby epithelial cells, and thereby curtail the otherwise logarithmic increase in viral load 
during an acute HRV infection. This suppression of viral population growth may provide 
the advantage necessary for the immune system to more rapidly resolve these infections, 
or in addition to the decease in viral number, it might result in less activation of the 
inflammatory immune responses attributed to many of the pernicious symptoms seen in 
common cold sufferers (121).  
 Clinical trials of Zn for the common cold have had highly variable effects on 
symptoms and their duration (122). One explanation for this outcome could be a 
consequence of the unknown etiology of the virus causing the common cold, as rapid 
diagnostic assays were not available at the time when many of these studies were 
performed. It is possible that the virus triggering the symptoms in many of the study 
enrollees was not due to the presence of an HRV, and with the ability of other upper-
respiratory viruses to be inhibited by Zn in doubt, this discrepancy could have 
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unwittingly contributed to a high amount of false-negative results when Zn-lozenges 
were tested. 
 An additional confounding factor may have been the formulation of the lozenge. 
The chelating sugars that were included in some lozenges to make them more palatable, 
may have dampened the ability of Zn+ to inhibit HRV infectivity. I have demonstrated 
that the presence of sucrose in the Zn cation milieu can result in chelation of Zn which 
prevents its HRV inhibitory activity in a tissue-culture assay (Figure 3.23). While 
relegated to a tissue culture model, this data nonetheless provides a cautionary framework 
when considering the formulation of future Zn-based HRV therapeutics.   
 









Diagram 5.1 Mechanism possibilities 
 1) HRV interaction with its cognate receptor. 2) Modulation of viral capsid metastability to a) 
dissemble the capsid outside of the host cell or b) lock the capsid structure, preventing viral 
genome release within the host cell cytoplasm. 3) Damage to the viral genome that prevents 
translation or recognition by host machinery 4) Agglutination of viral particles that decreases the 







Mechanistic hypothesis and experimental analysis  
 
The observation that extracellular exposure to Zn results in a decrease in viral titer led me 
to initially postulate 4 general hypothesis to account for this mechanism through 
contemplation of which key steps in the viral cell-entry and replication-initiation process 
could potentially be disrupted by the activity of this cation (Diagram 5.1. The plaque 
assays used to reveal this inhibition rely upon the cytopathic virus-induced death of 
infected cells. While high particle to PFU ratios have been reported in picornaviruses, the 
production of the plaques used to calculate virus titer necessitates that the virus or viruses 
responsible for plaque formation be intact and capable of initiating replicative events that 
will produce progeny virions. Exposure to Zn results in abrogation of this ability, an 
irreversible loss of, plaque-production. Seeking to learn more about the mechanism of 
this inhibition, I initially structured my research plan around investigation of each of 
these 4 key routes of inhibition that might be impeded by the presence of Zn.  
 
Zn does not interfere with receptor binding 
 
 Binding of the virus to its cognate receptor is required for endocytic access to the 
host cell cytoplasm and interference with this critical step in the infectious cycle has been 
the goal of many antiviral drugs. The ICAM1 receptor utilized by major group viruses 
and the LDLR receptor used by minor group viruses vary significantly in structure. The 
ability of Zn to inhibit both major and minor group viruses, albeit to varying degrees, was 
a provocative finding that implied that this inhibition might not directly involve virus-
receptor interaction. However, it was not out of the realm of reason that the general 
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activity of a cation in surplus could be inhibitory to both major and minor HRV receptors 
through a general mechanism such as occluding viral-receptor contacts of negative 
charge at the binding interface. To explore this possibility I performed experiments 
wherein I transiently incubated the HELA monolayer with Zn prior to viral infection and 
performed PBS washes prior to HRV infection. If Zn cations were impeding virus 
binding through association with sites of negative charge on the cell surface, I postulated 
that promoting this interaction prior to application of HRV would also result in a 
depressed viral titer. While this experimental process did not replicate the inhibition seen 
with HRV-Zn exposure in isolation, I felt that this result was inconclusive as the presence 
and concentration of Zn after the protective washes could not be confirmed (results not 
shown). To more clearly determine if Zn treated virions were still capable of interacting 
with their receptor, I developed a “competition assay” wherein untreated, infectious 
virions were forced to compete with Zn-treated HRV for a limited number of receptor 
binding sites. Necessitating the assumption that the amount of HRV is in excess of 
binding sites, this assay was performed using an extremely high MOI with the proportion 
of Zn-treated HRVs gradually increasing in the inoculate, while the amount of untreated 
HRV remained constant. Theoretically, in this assay, if Zn-treated HRVs are able to bind 
a cellular receptor, given their inability to initiate an infectious cycle, a decrease in total 
plaque number will be observed as the presence of these inactivated virions occupy 
binding sites that might otherwise be utilized by infectious particles whose replication 
cycle can result in successful plaque formation (Figure 3.18). The ability of this assay to 
demonstrate the existence of receptor-based competition was demonstrated using UV-
treated HRV virions whose RNA damage prevents the initiation of an infectious cycle, 
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despite the capsid remaining intact and capable of receptor binding (Figure 3.19). The 
decrease in plaque number seen as the amount of Zn-treated virions is increased 
paralleled that of UV-treated virions, indicating that Zn-treated HRVIA is still capable of 
interacting with its receptor. 
  Furthermore, in the ICPA, formation of plaques relies upon the binding of virus 
to the first batch of infected cells used to “seed” the second monolayer. In the ICPA I 
designed, holding cells at 4C was used to prevent endocytosis of virus particles after 
receptor binding. In this assay, plaque formation was only possible if HRV or PV was 
able to remain bound to its receptor for the duration of ZnG treatment, harvest and re-
suspension. The dearth of plaques seen in the Zn-treated group compared to the untreated 
group in this assay indicate that Zn-mediated inhibition of HRV is able to occur even 
after binding of HRV1A to the LDLR cell receptor (Figure 3.15). This result indicates 
that Zn access to the geographical area that encompasses the virus-cell receptor 
interaction, is not necessary for inhibition to occur, and in conjunction with the 
competition assay, it is not likely that Zn functions by unseating virions from their 
receptor. Taken together, the result of these experiments allowed me to eliminate the 
hypothesis that Zn plays a receptor-mediated role in HRV inhibition.  
 
Zn does not trigger extracellular capsid disassembly  
 
 Held together by non-ionic binding interactions, the capsid proteins that protect 
the viral genomic payload must play the dual function of safeguarding the viral genome 
outside of a host cell and also dissembling to release the genome once the cytoplasm of 
the host cell is reached. This potential energy imbued in the capsid structure that allows 
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for genome release is characteristic of the important “metastability” needed for the virus 
particle to remain infectious. Detrimental modulation of capsid metastability that results 
in premature genome release, or imprisonment of the viral genome after cell entry, has 
been the goal of numerous antiviral drugs (4). The ability of Zn to either promote capsid 
dissembly (Diagram 5.1, 2a) or lock the capsid structure in place (Diagram 5.1, 2b) could 
both account for the initial experimental outcomes I observed. However, complete capsid 
dis-assembly would remove the binding contacts necessary for the virus-cell receptor 
interaction. Therefore, the results of the competition assay made such a mechanism 
unlikely. Furthermore, viral capsid protein visualization through native and denaturing 
polyacrylamide gels implies that the interactions of Zn-treated capsids were not 
disrupted, and that Zn did not induced cleavage of these polypeptides (Figure 3.20 and 
Figure 3.21). While this result is not concrete due to the unavailability of an HRV1A-
specific antibody with which to probe these proteins blots, the unchanging pattern seen in 
both Zn treated and untreated groups that could be observed with both a coomassie stain, 
and a more sensitive silver stain, implies that  the totality of protein complexes, be they 
viral or cellular, are unchanged with Zn treatment. The possibility of Zn-treated viral 
capsid entry into the cell without genome release is not refutable with my experimental 
results. Further exploration visualizing the location of labeled virions could reveal the 
validity of this hypothesis, however, the small size of picornaviruses does not make them 
amenable to fluorphore labeling. Using radiolabeled virions, one could determine if Zn-
treated virions are capable of cellular entry, however, additional experimental measures 
would need to be taken to determine if the capsid structure has remained intact as cell 
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entry with no replication is possible if the viral genome is no longer capable of being 
recognized and translated by host ribosomes.  
 
Zn treatment results in degradation of viral RNA  
 
 The HRV genome consists of a single, naked strand of RNA with extensive 
secondary structure that forms an IRES that allows for its immediate translation upon cell 
entry. This RNA serves as both the template for the creation of more genomic RNA, and 
as an mRNA template for viral protein synthesis. To initiate a successful infectious cycle, 
this RNA must be recognized by host cell translation machinery and the viral proteins 
necessary to carry out other stages of the replication cycle must be created. Without an 
intact genome, the infectious cycle cannot proceed, therefore, the potential of Zn to 
catalyze damage to viral RNA genome was investigated (Diagram 5.1, 3). Initial 
tabulation of RNA quantity after isolated of HRV1A by centrifugation and Zn treatment 
revealed that the total amount of RNA had decreased compared to an equivalent aliquot 
of untreated virus (Figure 3.23). Furthermore, assaying for HRV-specific RNA in Zn-
treated and untreated fractions after sucrose gradient purification revealed a decrease in 
detectable viral genomic material, and that the location of RNA in the centrifugal milieu 
did not change with Zn treatment (Figure 3.24). Additional HRV-specific probing of 
Northern blots after Zn treatment revealed the disappearance of full-length HRV RNA, 
and the general decrease in higher molecular weight viral RNA, despite the length, or the 
specificity of the probe used (Figure 3.25, Figure 3.26 and Figure 3.27). Rnase inhibition 
used in these experiments removed the possibility that this RNA degradation is the result 
of the presence of contaminating Rnases. These results indicate that hypothesis 3 is valid 
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and that RNA catalytic activity is at least partially responsible for the extracellular Zn-
inhibition observed. However, the ability of Zn to promote HRV inhibition through an 
additional mechanism is also possible. Furthermore, the means by which the presence of 
Zn promotes this RNA degradation is not certain. However, the results of the competition 
assay, ICPA assay and the fact that remnants of viral RNA are found to sediment 
equivalently to untreated HRV, suggest that this process does not dramatically alter the 
HRV capsid structure. Without dis-assembly of the capsid, Zn mediated catalysis of 
genomic RNA likely occurs after entry of this cation into the capsid structure wherein it 
might form an RNA cleaving nuclease with interior histidine residues. Bolstering this 
conjecture is the documented ability of similar element, Cesium, to enter the capsid, and 
the presence of a pore on the capsid surface as visualized through 3 dimensional 
molecular imaging based upon biophysical investigations into HRV capsid structure 
(Figure 5.2) (4). 
 
Zn is not inhibitory due to capsid agglutination  
 
 Zn-mediated agglutination of HRV capsids would also potentially result in the 
inhibition observed here. However, agglutination in this manner is unlikely to be cation-
specific. The inability of other 2+ cations tested to replicate this HRV inhibition 
discredits this hypothesis, in addition to the unlikelihood of such aggregates remaining 
intact through the process of dilution, vortexing and plaque assay preparation (Figure 
3.11). Furthermore, the indiscriminate formation of aggregates in HRVs alone, and not 
the other the picornaviruses tested to any degree, is unlikely. Given the similarity in 
capsid structure, at least a modest degree of agglutination would probably be seen in 
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different picornaviruses, even if not to the same degree of that seen in HRVS. 
Furthermore, cloudy precipitate, which might be indicative of aggregate formation, was 
never observed in any of the HRV-Zn mixtures tested.  
 
Zn-mechanism conclusion  
 
 Taken together, the results of the northern blot analysis, competition assays and 
sucrose gradient fractionation suggest that the primary mechanism of Zn based inhibition 
of HRV1A involves the degradation of viral RNA, thereby reducing viral infectivity. 
Given the results of the competition assay and ICPA assay, which together imply that the 
interaction of the virus and its receptor is neither required for, nor disrupted, by Zn 
activity, I hypothesize that Zn enters the HRV1A capsid where it participates in 
degradation of the viral RNA while the viral capsid remains wholly or partially intact. In 
further support of this hypothesis, it is known that cesium, an element of similar size to 
Zn, can enter the HRV capsid, possibly through a pore at the 5–fold axis of symmetry (4). 
Given the similar size and clinical profile of these two cations, it is plausible that Zn may 
also enter the viral capsid in a similar fashion. However, Cesium - mediated degradation 
of viral RNA has not been reported. In contrast, the capsid of poliovirus is not permeable 
to cesium, and similarly, Zn does not inhibit the infectivity of this virus. While RNA 
degradation from Zn-treatment is documented, it cannot yet be disproved that additional 
mechanisms may be at play. It is also possible that Zn binding or entry into the viral 
capsid may alter the metastability of the structure, resulting in downstream difficulties 
with virion internalization and un-coating. However, without intact genomic RNA, such 




Zn-resistant HRV mutations 
 
  To understand the mechanism of Zn-mediated inhibition of HRV1A, I sought to 
scrutinize differences between Zn-sensitive and Zn-resistant HRV1A. While exposure to 
Zn is tremendously detrimental to HRVs, completely eliminating evidence of infectious 
virus in some experiments, infrequently, infectious HRVs can be detected after Zn 
treatment at more moderate concentrations. However, it was unclear if the existence of 
these infectious particles after ZnG is due to genetic resistance to Zn-mediated inhibition, 
or if insufficient Zn was available to abrogate the infectivity of every viral particle in 
solution, despite attempts to quantify the amount of virus particles to Zn cations in cases 
of 100% inhibition.  
 
Procedure and caveats  
 
Given the highly mutagenic-ability of RNA viruses, whose polymerase lacks proof-
reading functionality, considerable genetic diversity exists in any HRV population 
naturally, often leading them to be described as “quasi-species”(4). While it may be 
responsible for the high particle to PFU ratios often reported with picornaviruses, this 
genetic diversity provides the evolutionary potential for the existence of virions that 
contain advantageous mutations that allow for survival under various conditions. 
Consequently, I presupposed that within a sufficiently large population, it would be 
statistically likely that Zn-resistant HRVs exist and might be selected for under the 
consistent selection pressure of Zn. However, given the cytotoxic nature of sustained Zn 
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exposure, relentless Zn-pressure was not possible, given that healthy HeLa cell metabolic 
activity is necessary to support viral replication. To prevent cell death that would limit 
virus production, I developed a Zn-resistant HRV cultivation strategy wherein I 
sequentially exposed HRV populations to Zn, removed excess Zn with EDTA prior to 
HeLa cell infection, and then subjected each viral harvest to an increasing amount of Zn 
exposure. In doing so, it was immediately apparent that resistance to Zn came at a cost of 
general darwinian fitness of the virus particles. In addition to a smaller plaque phenotype, 
Zn-resistant HRV1A titers never rivaled those of their wild-type progenitors. The reason 
for this stark decrease in Zn-resistant HRV1A fitness remains unexplained, but it is most 
likely due to disadvantageous interactions between the viral proteins which affect capsid 
assembly, disassembly, or selective encapsulation of viral RNA. To analyze genetic 
differences between wild-type and Zn-resistant HRV1A, I designed a series of over-
lapping primers that collectively covered the entire HRV1A genome and whose similar 
Tm allows the forward and reverse members to be interchanged to adjusted amplicon size 
as needed. Alignment comparisons among NCBI HRVIA sequence submissions and 
wild-type control virus isolates subjected to the same procedure revealed genetic 
differences in these strains that might account for the Zn-resistance phenotype.   
 
Summary of mutations     
 
 After cultivation, isolation and sequencing analysis of Zn-resistant HRV1A, three 
different amino-acid substitutions in the VP1 capsid polypeptide were found in six 
different Zn2+-resistant isolates. Each of these mutations was found in multiple Zn-
resistant isolates, alone or in combination, and in none of the wild-type, Zn-susceptible, 
 
 121 
control HRV1A preparations. The change in residue charge of two of the three mutations 
in the HRV VP1 protein found here could play a biochemical role in repelling Zn from 
entering the capsid while the third mutation might provide steric hindrance or 
stabilization of the capsid structure. In addition, it has been previously documented that 
interaction of Zn+ with the imidazole ring of histidine can lead to the formation of a 
nuclease which can catalyze degradation of RNA (4). It is plausible that a similar 
interaction of Zn+ with histidines in the capsid interior could precipitate the destruction 
of viral genomic RNA. Therefore, a mutation, which helps to exclude Zn entry into the 
viral capsid, might provide a protective role. While not indisputable, a mechanism such 
as this, which does not require extensive disruption of the viral capsid, or exit of the viral 
RNA from the capsid structure, is in line with the salient findings presented here. Cesium 
has not been documented to participate in a similar nuclease mechanism, perhaps 
explaining why its entry into the viral capsid is not reported to result in viral RNA 
degradation. 
 
Residue 29 on VP1  
 
 The VP1 capsid protein is predominantly outward facing, but does display 
inward-projections into the capsid interior which may play a role in capsid stabilization, 
interaction with other capsid proteins, or genome interaction. In multiple Zn-resistant 
isolates, an amino-acid transition at the interior residue 29 on VP1 was found in 
conjunction with mutations on the surface-facing region of VP1. Because the amino acid 
alteration at position 29 was not observed independently, the possibility of this mutation 
playing a singular, definitive, role in Zn resistance is not concretely validated. However, 
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it is important to note that its representation in just 6 isolate samples may not provide the 
most comprehensive statistical census of its presence among Zn- resistant HRV 
populations. With time and additional Zn- resistant mutant isolation, it’s existence in the 
capsid structure as a singular mutation conferring Zn-resistance would not be an 
unprecedented discovery given the limited scope of Zn-resistant mutants surveyed here, 
due to time and practicality considerations. Furthermore, only the most Zn-resistant 
HRVs were sequenced. It is possible that some of the intermediately resistant populations 
might contain this mutation. The observation of this specific residue 29 mutation in 3 out 
of 6 mutant VP1 proteins rendered, supports the belief that this mutation is not the result 
of random bottle-neck carry-over after Zn-mutation selection, as this would be 
statistically unlikely to have occurred in 3 of 6 separate isolation events. It is much more 
statistically reasonable to assume that even if not playing a direct role in in Zn-repulsion, 
that this mutation might play a stabilizing or supporting role for its external counterparts.  
This amino acid is part of the VP1 loop that projects into the capsid interior, coming into 
close proximity to viral genomic RNA. This geographical feature, combined with its 
juxtaposition to two histidine residues on residues 24 and 25 of VP1 residing near it 
within the capsid interior, makes the aforementioned imidazole nuclease-based catalysis 
of the viral RNA genome plausible for the wild-type version of HRV1A. However, the 
positively charged lysine in the Zn-resistant variant may also act to repel Zn from this 












Diagram 5.2  Mutation at residue 29 in VP1.  
Asparagine in wild-type HRV1A transitions into Lysine with Zn selection. 
 
Furthermore, the presence of this positive charge within the capsid structure may function 
by providing an additional degree of Zn protection in the event that the exterior 
mutation(s) did not provide a strong enough deterrent for preventing Zn entry into the 
capsid. This mechanistic possibility is bolstered by the observation that three Lysine 
residues surround the interior side of the pore due to the repetitious nature of protomeric 
capsid protein interactions that comprise the icosahedron. The collective net positive 
charge that this mutation lends to the capsid structure through it’s 60-fold repetition in the 
complete capsid, in conjunction with one of the other surface mutations, could result in a 
profound biochemical change to the capsid structure. This amino acid biochemistry 
change on residue 29, in combination with an additional positively charged surface 
residue, or in conjunction with a surface residue lending steric inhibition to capsid pore 
entry, might additively result in successful avoidance of Zn-catalyzed damage to viral 
RNA. Furthermore, the “breathing” seen in HRV capsids, wherein a transient 135S 
particle is formed by extrusion of VP4 and the interior N-terminus of the VP1 protein on 
which this mutation site resides, may put this residue in a position to more directly repel 
Zn (4) when projected outside the capsid structure. Alternatively, this or any of the other 
mutations found might play a role in prevention of 135S particle formation, and thereby 


























Figure 5.1 Asparagine 29 in the 
capsid interior.  
The Asparagine 29 on HRV VP1 (purple) can be seen dipping into the capsid interior through 






















Figure 5.2 Asparagine 29 proximity to capsid pore  
The Asparagine (Asp) 29 in HRV VP1 (purple) can be found in the capsid interior near the 
capsid pore. The repeating protein interactions that form the capsid results in three Asp 29 
residues surrounding the pore entrance (labeled in white)  
 
Residue 87 on VP1  
 
In 3 out of the 6 Zn-resistant mutant HRV1A isolates characterized, the 87th residue of the VP1 
protein transitioned from a Threonine to a Serine. This residue is found on the antigenic “B-C 
loop” protruding off the HRV1A surface near a clearly visible pore structure.  This B-C loop has 
previously been described to play a role in multiple anti-picornaviral drug mechanisms. While 
vaguely similar in size and structure, a distinguishing characteristic that differentiates these two 
amino acid residues is the documented biochemical hydrophobicity displayed by the wild-type 
Threonine that is not seen in the Zn-resistant Serine residue. Consequently, in the aqueous 
solutions in which HRVs are typically found, this defining biochemical characteristic may 
catalyze a conformational change in the B-C loop due to the Threonine side-group’s avoidance 
of polar solutions. This potential hydrophobicity-driven conformational change would not occur 














Diagram 5.3 Mutation at residue 87 in VP1.  
Threonine in the wild-type HRV1A transitions into Serine after Zn selection. 
 
Given its proximity to the pore structure, one could also postulate that such a conformational 
discrepancy might culminate in steric prevention of Zn access to the pore, preventing Zn entering 
the viral capsid. However, without detailed molecular modeling techniques coupled with 
biophysics experimentation to confirm conformational changes, this proposed mechanistic role is 
just an informed conjecture.  
 
Residue 91 on VP1 
 
 Also in the B-C loop structure on the surface of the viral capsid, the 91st glycine 
residue of VP1 has been found to transition into a positively charged arginine residue in 
multiple Zn-resistant isolates. In addition to its positive charge, the chemical structure 
















Diagram 5.4  Mutation at residue 91 in VP1. 
 Glycine in the wild-type HRV1A transitions to Arginine after Zn-selection.  
 
Due to it’s biochemistry, repulsion of Zn cations from the viral capsid is the most obvious 
potential mechanism of this mutation, especially when one considers that this mutation is 
replicated 60- fold around the capsid structure and lies near the pore structure on the 5-
fold axis. Furthermore, this positive charge is found on the end of an elongated side 
group, consisting of a chain of 4 carbon atoms, which might result in pore-protecting 
steric hinderance, or projection of the positive charge outward in a manner that may be 
additionally conducive to Zn-repulsion.  
In general, the conformation and flexibility of the VP1 B-C loop is known to play 
a role in the inhibition of picornaviruses by the antiviral compound plecornaril and other 
similarly structured drugs (69). Therefore, the presence of these two mutations on the B-
C loop, just 3 residues adjacent to one another, and the impact such mutations might have 
on the conformation and flexibility of the B-loop, makes this locale an unsurprising hot-






Zn-resistant HRV1A fitness cost 
 
The decrease in fitness of the Zn-resistant isolates compared to their wild-type 
counterparts is staggering. In achieving a degree of resistance to Zn-catalyzed inhibition, 
these viruses loose efficacy in one or more stages of the viral infectious cycle, such as 
receptor binding, capsid un-coating, or assembly. Given that Zn-treated virions have 
demonstrated the ability to bind the LDLR receptor securely as demonstrated by the 
competition assay and the ICPA assay, it is more plausible that this decrease in fitness is 
due to mechanistic challenges that these biochemical or conformational changes lend to 
the un-coating or capsid assembly process. However, it is important to note that the B-C 
loop structure of VP1 contains binding contacts that interact with the ICAM-1 receptor 
and the B-C loop structure may also play a role in LDLR binding of minor group HRVs. 
Therefore, the presence of one or more mutation sites within the B-C loop might disfavor 
the successful virus-receptor interaction critical for virus internalization.  Another 
possibility is that the presence of these substitutions in the singular HRV ORF decreases 
the efficiency of polyprotein processing and self-cleavage mechanisms that then results in 
a decrease in the production of cogent capsid proteins capable of assembly. Aside from 
plaque formation, a significant difference in cytopathic effect (CPE) between Zn-resistant 
and Zn-sensitive HRVs was not observed before or after fixation and staining of infected 
HeLa cell monolayers. 
 While the development of resistance is a concern for any antiviral product, the 
demonstrated high fitness cost that is associated with resistance to Zn+ suggests that 
resistant HRVs are unlikely to evolve to become the predominant endemic genotype 
circulating in any HRV population. Up to half a dozen serial passages were unable to 
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return the Zn-resistant populations isolated in this study to titers comparable to that of 
their wild-type predecessors. While this decrease in fitness might be attributable to a 
detrimental “bottle-necking” effect wherein deleterious mutations are stochastically 
inherited in conjunction with the beneficial Zn- resistance mutation, this is unlikely due 
to the lack of evidence of such mutations when genome-wide sequencing analysis was 
performed.  
 
HRV inhibition mediated by Zn Ionophores 
 
Previously, ionophores Pyrithione (PT), Hinokital (HK) and PDTC have been 
documented to inhibit HRV and other viruses through interaction with intracellular 
factors during viral replication. The presence of a Zn cation, or Copper in the case of 
PDTC, was shown to be required for their intracellular inhibitory activity (123). 
Extracellular picornavirus inhibition with Pyrithione and Hinokital has not been explored, 
and extracellular exposure with PDTC alone failed to inhibit HRVs (293). Here I have 
demonstrated that PT, HK and PDTC can inhibit HRVs through an extracellular 
mechanism that requires Zn. The concentrations of Zn required to see HRV inhibition in 
conjunction with these compounds is significantly less than that needed to see inhibition 
of HRVs with Zn alone. Like EDTA, these compounds have the ability to chelate Zn 
from solution and prevent HRV inhibition; an activity that is optimized at characteristic 
ratios based upon their stoichiometry of complexation with Zn cations. However, their 
sequential interaction with Zn and HRVs, alone or in combination, can result in 
protection from Zn-induced inhibition, or an escalation of loss of infectivity. It is unclear 
if the antirhinoviral activity of these compounds in conjunction with Zn operate by 
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enhancing the mechanism seen with Zn-alone, or if they facilitate a distinctive 
mechanism of HRV inhibition.     
 
Hinokital - mediated Zn Inhibition  
 
Hinokitiol, also known as Beta - thajaplicin, is a derivative of wooded plants from the 
Cupressacae family and has been noted for its ability to inhibit certain strains of 
chlamydia and streptococcus, in addition to modulating estrogen receptor signaling and 
inducing suppression the of the inflammatory response in vascular smooth muscle cells 
(124). It has also been noted for its anti-fungal properties and potential to modulate 
cancer-related cell-signaling pathways (125). Past research with HRVs, PV, CVB3 and 
mengovirus suggested that this compound, in conjunction with Zn or Cu, could impede 










Diagram 5.5 Chemical structure of Hinokitiol   
 
 I found that Hinokitiol alone did not possess the ability to decrease HRV 
infectivity through extracellular exposure. However, abrogation of HRV infectivity with 
this compound in conjunction with Zn was dramatic to the extent that the minimum 
concentration required to see inhibition was not breached. However, addition of this 
chemical to HRV1A inoculates resulted in the immediate formation of a cloudy 
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precipitate that was visible throughout the solution. Hinokital solutions supplemented 
with DMSO did not reduce the production of this precipitate, and both ZnG and ZnCl 
yielded similar results (Figure 4.1). The existence of this visible precipitate created 
worries that it’s antiviral activity was mitigated partially through aggregate formation or 
occlusion of access to the viral receptor. However, this HK-Zn precipitate did not inhibit 
PV. The inability to inhibit PV suggests that the mechanism of this compound is not 
attributable to generalized agglutination and indiscriminate receptor occlusion.   
 
Pyrithione - Mediated Zn Inhibition 
 
The Zn – Pyrithione (PT) coordination complex has been studied for its antifungal and 
bactericidal abilities (126). Furthermore, it’s ability to ameliorate dandruff and Seborrhoeic 
Dermatitis have promoted its incorporation into medical and over-the-counter products (127). 
Virology-based research with this compound has revealed its ability to inhibit the Herpes 
Simplex Virus as well as coronanavirus and arterivirus through mechanisms that impede 
proteasome function, RNA polymerase activity and NF-kappaB activation. Past research with 
HRVs, PV, CVB3 and mengovirus suggested that this compound, in conjunction with Zn or Cu, 
could impede picornaviral polyprotein processing when introduced into an infected cell. 
Investigation into its possible extracellular effect on picornaviruses alone or in conjunction with 
Zn was not reported (117). Using concentration ranges similar to those employed for intracellular 
studies, I found that extracellular exposure to PT alone did not produce HRV inhibition, even at 
quantities that vastly exceeded that used in prior research. However, substantial inhibition of 
both major and minor group HRVs was observed when this chemical is used with the 
supplementation of Zn. In these experiments less Zn was required to elicit inhibition of HRVs 
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than that required for Zn-based inhibition alone. The degree of inhibition seen in experimentation 
with HRV1A, HRV16 and HRV39 was essentially equivalent, though not extensively 
scrutinized. Unlike Hinokitiol, addition of PT alone or in combination with Zn to HRVs in 
solution did not produce a visible precipitate and this inhibition was observed with both ZnG and 







Diagram 5.6  Pyrithione and Pyrithione Zn Salts.  
The structure of a single Pyrithione salt molecule  (A), and two in complex with a Zn cation (B).  
 
 The relationship between PT, Zn and HRV inhibition is procedure dependent and 
stochiometrically modulated. PT is known to be able to chelate Zn cations at a ratio of  
2:1. When PT is mixed with Zn at a ratio of 2:1 prior to HRV exposure, the effect is 
protective and the infectious titer of the HRV is not significantly decreased, similar to 
that seen in experiments with EDTA. Likewise, when PT is added to HRVs in solution, 
prior to ZnG supplementation, inhibition is mitigated, most noticeably at a ratio or 2:1. In 
both of the above scenarios, a 1:1 ratio of PT to Zn was less effective at preventing HRV 
inhibition, while a 3:1 ratio provided a protective effect, but one that was less defensive 
than a ratio of 2:1 (Figure 4.1, Figure 4.5, Figure 4.6 and Figure 4.7). However, unlike 
EDTA, not only did addition of PT after Zn-treated of HRV fail to reverse HRV 
inhibition, but it also vastly increased the scale of inhibition. This increase in inhibition 
appeared to be optimized at a PT to Zn ratio of  2:1 and minimized at a ratio of 1:1. A 
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ratio of 3:1 was capable of augmenting the amount of HRV inhibition, but not to the 
same degree as that seen with 2:1 ratios.  
 The mechanism behind this exacerbation of Zn- involved HRV inhibition after PT 
addition is unclear. PT may act by synergistically amplifying Zn-mediated inhibition, or 
by additively providing an alternative mechanism of HRV inhibition that is unique to the 
Zn-PT compound. The inability of PT and Zn in ratios of 1:1 or 1:3 to replicate the effect 
seen with ratios of 1:2 implies that characteristics specific to the di-Zn-PT complex are 
critical. These observations also suggest that the theoretical presence of PT molecules 
bound to a single Zn cation behave in a  very different manner, neither facilitating, nor 
protecting, the HRV structure from Zn-mediated damage.  
 
PDTC - mediated Zn Inhibition 
 
Pyrrolidine dithiocarbamate (PDTC) has been studied for its ability to modulate physiological 
processes such as G1 cell cycle arrest, nitric oxide synthase production and NFkappaB activity. 
Furthermore, PDTC has been reported to possess bacteriacidal abilities in the presence of ZnCl 
(118). Recent studies on its potential antiviral properties revealed the ability to inhibit herpes 
simplex virus 1 and 2, enterovirus 71 and coxsackieB3 virus replication through a mechanism 
involving the dis-regulation of the ubiquitin-proteasome system (291). Furthermore, a study with 
influenza, poliovirus and HRVs cited its ability to repress viral replication through inhibition of 
viral polyprotein processing (123). Research targeted on HRVs documented that intracellular 
PDTC could impede the replication of HRV1A, 2, 14 and 16, as well as poliovirus, through 
interference of viral protein expression (111). Notably, the intracellular inhibitory action of 
PDTC in all these cases was shown to rely on the presence of metal cations such as Zn or Cu. 
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However, while interesting in itsown right, these documented mechanisms of PDTC inhibition 
are not specific to HRVs and require access to the intracellular milieu of an infected cell. While 
these prior studies indicated the necessity of Zn to potentiate PDTC antiviral activity, and 
observed that PDTC was not inhibitory to HRVs with extracellular exposure, no experimentation 






Diagrams 5.7  Pyrrolidine Dithiocarbamate (PDTC) structure. 
 
 The structure of PDTC has allowed chemists to diagram its theoretical interaction with 
Zn cations. Biochemically, PDTC can form aggregate complexes with Zn at a PDTC to Zn ratio 
of 2:1, however the prevalence of larger compounds with the same stoichiometry and their 
relevance to biochemical processes is not known (4). Based upon my findings with other 
ionophores, I sought to determine if PDTC might be able to demonstrate extracellular inhibition 
of HRVs when supplemented with ZnCl or ZnG. Using concentration ranges similar to that seen 
in intracellular studies of viral inhibition, I subjected HRVs to PDTC in combination with Zn. 
The concentrations of Zn used in these assays are more than ten-fold lower than those needed to 
see HRV-inhibition with Zn alone. The lack of HRV titer decrease I observed after treatment 
with PDTC alone, or Zn alone at low concentrations, was expected. Remarkably, however, 
inhibition of HRV1A could be demonstrated only when the precipitate from the chemical 
interaction of PDTC and Zn was harvested, re-suspended, and added singularly to HRVs in 
solution. Adding PDTC and Zn sequentially, or vice-versa, did not yield any decrease in viral 
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titer. Furthermore, isolation of this precipitate from its reacting solution appears necessary for 
optimal HRV inhibition, and the yield of this product is increased with heat. Both ZnCl and ZnG 
formed an identical precipitate with PDTC, however, reaction of PDTC and Zn at different ratios 
produced precipitates that appeared slightly different in crystalline texture when observed with 
microscopy after isolation and drying of the sample. Preliminary results with PV and EV68 did 
not demonstrate any inhibition to extracellular PDTC or to this Zn-PDTC compound, suggesting 
that there might be an HRV-specific mechanism at work.  
 This PDTC and Zn mediated extracellular inhibition of HRVs has not been published in 
prior literature. Given that this inhibitory activity excluded PV, it is unlikely that this mechanism 
functions to generally inhibit many viruses like that observed in intracellular studies. However, 
like PT and HK, the synergistic or additive relationship of this mechanism to that of Zn has not 
been determined.  
Clinical relevance of Research    
 
 While acute HRV infections may not be life-threatening to the average healthy 
adult, they pose a great risk to the geriatric, neonatal, immune compromised, asthmatic 
and those suffering from cystic fibroses and other respiratory diseases (128). 
Furthermore, the morbidity and workforce absenteeism caused by HRV infections in 
healthy adults is estimated to have a profound impact on economic productivity and 
quality of life (4). Consequently, there is a significant medical and economic imperative 
to develop an efficacious therapeutic with the ability to abate the duration and severity of 
HRV infection symptoms in healthy adults, and to protect the vulnerable populations for 
whom contact with these viruses is more life threatening. Unfortunately, the widespread 
circulation of numerous HRV genotypes has hindered development of a vaccine, and 
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current antiviral compounds against HRVs have shown little therapeutic success (129). 
However, the poor outcome of many clinical trials, and the lack of a specific mechanism 
to explain the anti-rhinoviral activity of Zn, has prevented further development of Zn-
based products. The insight into the mechanism of extracellular Zn inhibition of HRVs 
presented here might serve to focus the optimization of Zn-based therapeutics, or 
template the design of novel small-molecule antiviral inhibitors that may have a similar 
mechanism.   
Future Directions  
 
The potential to use Zn compounds or Zn Ionophores for anti-rhinoviral 
therapeutics had undeniable potential. However, detailed knowledge of the precise 
mechanism of Zn antiviral activity is necessary to optimize these products and progress 
forward. In this body of work I have demonstrated that there is an extracellular 
mechanism of Zn-based HRV inhibition that results in RNA degradation. However, the 
exclusivity of this mechanism is not clear and further research on additional routes of 
HRV infectivity abrogation should be probed, such as deeper investigation into the 
impact of Zn on viral capsid proteins or capsid metastability.  Additional experimentation 
using custom-developed antibodies and electron microscopy to examine the integrity of 
the viral capsid after Zn treatment would be advantageous. While the small size of  
picornaviruses makes stable incorporation of fluorophores problematic, differential 
sedimentation of Zn treated and untreated radio-labeled virions may also help 
characterize the viral capsid after Zn treatment.  
  Furthermore, while this study focused upon HRV1A, more in-depth 
characterization of additional HRV species should be performed, including the 
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examination of mutant isolates. It is very likely that major group HRVs may require 
different mutations in the viral capsid proteins to gain Zn resistance, and comparison of 
these mutations to that seen in HRV1A and other minor group HRV representatives may 
provide more information about the mechanism at hand. Furthermore, the impact of Zn 
compounds on the newly characterized HRV-C species should be investigated, especially 
considering the clinical impact of these newly-characterized viruses. Competition and 
ICPA assays using a major group isolate representative might reveal if receptor binding 
in these HRVs appears to be likewise unaffected, or uninvolved in the inhibitory 
mechanism, respectively. 
 The promising results presented here on the use of Zn in conjunction with 
ionophores may only be the metaphorical tip of the iceberg when it comes to the potential 
use of these compounds. Showing substantial HRV1A inhibition with less Zn required, 
HK, PT and PDTC have demonstrated enormous potential to be used with Zn in antiviral 
therapeutics. PDTC has also been characterized to be physiologically amenable for 
possible clinical applications. High levels of Zn can be both unpalatable and detrimental 
to cells in the naso-pharynx. Zicam, whose Zn-based nasal spray is one the most popular 
over the counter treatments for the common cold, has endured lawsuits from individuals 
claiming to have experienced long-term detrimental side-effects with use of this product, 
and these claims were backed up by research on the effect of high Zn concentrations in 
the nasal cavity. Therefore, the ability of these ionophores to effectively inhibit HRVs in 
the presence of up to a ten-fold or lower Zn concentrations, might allow for the creation 
of safer Zn-based therapeutics. Furthermore, the current commercial use of Pyrithione in 
cosmetic products, and the animal research with PDTC, already demonstrates the 
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potential of these compounds to be clinically amenable for medical use. Experimentation 
with these compounds and different formulations of Zn with more representatives from 
the major and minor HRV groups should be conducted as well as with HRV-C. Similar 
steps like that shown here with ZnG and ZnCl, should be undertaken to determine if the 
mechanism of these compounds with Zn mirrors that of Zn alone, or acts using a different 
mechanism. Further characterization of the efficacy of these compounds on Zn-resistant 
mutants would be telling as well as the characterization of mutants arising from treatment 





   





Extracellular Route of  Zn Inhibition  
 
Here I have demonstrated that extracellular exposure alone to ZnCL, ZnG, or Zn in conjunction 
with Zn ionophores, can result in a decrease in the infectivity of an HRV population. This 
decrease in infectivity occurs quickly, is pH-dependent, and slightly elevated at higher 
temperatures. This inhibition was documented with both major and minor group HRVs which 
interact with different receptors when gaining entry into the host. Other similar picornaviruses 
such as PV, EMCV, CVB3 and EV68 are not susceptible to this inhibition, and other 2+ cations 
like Mg+, Mn+ and Ca+ do not inhibit HRVs. This inhibition cannot be reversed by the presence 
of a Zn-chelating compound, but can be prevented by the presence of  EDTA, Pyrithione and 
Sucrose. 
Inhibition Characterization  
 
This inhibition was characterized by examining the possible mechanistic routes that could 
accommodate the observations seen. These mechanistic routes were systematically investigated. 
The competition assay revealed that Zn-treated HRV1A could still interact with the LDLR 
receptor, a finding which indicated that Zn did not inhibit HRV1A by direct occlusion of the 
virus-receptor interaction. Furthermore, the results of the ICPA assay revealed that access to the 
virus-receptor interface was not necessary to illicit Zn-based inhibition of HRV1A, and that this 
inhibition can presumably still occur after the virus has formed a stable interaction with the 
LDLR receptor. Impeding infectivity due to virion agglutination is also unlikely, given that this 
inhibition was not seen with other 2+ cations which would likely have mediated the same type of 
non-specific mechanism, and this inhibition was not observed with other picornaviruses whose 
capsids share similar biochemical features. Dissolution of the virus capsid after Zn treatment, 
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leading to pre-mature release of the viral genome, is unlikely due to the sustained ability of the 
Zn-treated virion to interact with it’s receptor as seen in the competition assay. The lack of 
migratory differences between untreated and Zn treated viral proteins on native and denaturing 
gels also bolsters this notion. While the failure of viral genome release after entry into the cell is 
not implausible given my results, the apparent degradation of the viral genome after Zn treatment  
makes this outcome potentially irrelevant when considering the ultimate cause of infectious 
failure.  
Experimentally Supported Mechanism  
 
The observations outlined in this body of work support the notion that exposure of HRVs to Zn 
compounds results in catalytic degradation of viral RNA. A decrease in the amount of overall-
RNA and virus-specific RNA is seen after Zn treatment in both sera and sucrose gradient 
HRV1A fractions. This decrease in RNA after Zn treatment was observed via 
spectrophotometry, agarose gel visualization of HRV1A-specific PCR amplicons after reverse 
transcription using random hexamers, and northern blot analysis. While observation of the full-
length HRV1A genome was tenuous, a profound decrease in the amount of higher-weight RNAs 
after Zn treatment was seen in every northern blot, irrespective of probe size and experimental 
conditions. Incubation of HRV1A samples with Rnase inhibitors prior to Zn treatment implies 









Zn-Resistant HRV1A Mutations  
 
In an effort to characterize this inhibition, the genetic discrepancies between Zn-resistant and Zn-
susceptible HRV1A populations were investigated. Three mutations where found in multiple Zn-
resistant population isolates, alone or in combination, that could not be found in any Zn-
susceptible, wild-type control isolates also sequenced. All three mutations were found in the 
HRV1A VP1 protein, which comprises the bulk of the capsid structure. Two of these mutations, 
threonine to serine on residue 87 and glycine to arginine on residue 91, were found on an 
outward facing structure known as the “B-C loop” whose conformation has been suspected to 
play a role in other anti-rhinoviral drug mechanisms. The amino acid substitution resulting from 
each single nucleotide point mutation might play a role in chemically repelling Zn or occluding 
Zn entry through the capsid pore structure. One mutation, asparagine to lysine on the interior-
facing residue 29 might promote the repulsion of Zn chemically which could prevent the entry of 
Zn into the capsid where catalytic degradation of the viral RNA might occur. The mutation on 
residues 87 and 91 were found both in combination and singularly in some of the isolates 
sequenced, however, the mutation on residue 29 was only seen in combination with that of a 
surface residue. The reason for this is unclear, but may simply be the result of having sequenced 
an insufficient amount of samples to have discovered the existence of this mutation singularly, or 
might be due to the necessity of it’s coupling to another mutation for stability or efficacy.  
 
Efforts were taken to clone, transfect and propagate synthetic Zn-resistant HRV1A 
mutants. While the cloning strategy was a success, after transfection and numerous passages, 
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these viruses continually languished and failed to propagate at titers amenable for downstream 
experimentation. This outcome is not surprising due to the steep decrease in fitness observed in 
Zn-resistant viral populations. However, it may also be the case that only the mutation on residue 
29 of VP1 can exist singularly, and the mutations on residues 87 and 91 must be stabilized by 
additional mutations to create a viable HRV1A population. The reason for this decreased fitness 
is unclear, but is most likely due to disruption of the capsid assembly process caused by the 
change in charge at these residue sites, and possibly by the change in polypeptide conformation 
that accompanies them which may impede the interaction of VP1 with other capsid proteins and 
viral genomes during the assembly process. Furthermore, due to the self-cleaving proteolytic 
cascade characteristic of picornaviruses, it is possible that mutations at these sites prohibits or 
makes this cleavage cascade less efficient.  
 
Zn-Ionophore mediated inhibition of HRVs 
 
In addition to Zn alone, Zn in association with Zn-binding ionophores was also shown to be 
inhibitory to HRVs without being inhibitory to PV. In many cases, the degree of inhibition 
observed was far greater than that which could be seen with the same concentration of Zn in 
isolation. Hinokitiol (beta thalujaplicin), pyrithione and pyrrolidine dithiocarbamate were all 
found to inhibit HRVs when in combination with Zn, but not in isolation. This inhibition 
required HRV exposure to these compounds in a sequential order, or in the case of PDTC, 
chemical reaction of this compound with Zn prior to HRV1A treatment. Furthermore, the ratio of 
the ionophore to Zn appears to modulate the level of inhibition, or prevention of inhibition, seen. 
The ratios observed to maximize HRV inhibition coincide with the amount of Zn cation 
interaction sites of each ionophore based upon chemical structures. It is unclear if this inhibition 
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optimizes the mechanism of that seen with Zn alone, or inhibits HRVs through a unique 





Summary of Conclusions and Implications  
 
 The ability of Zn to dampen the replication of HRVs in tissue culture was first observed 
over 4 decades ago. Despite ambiguity as to the inhibitory mechanism of Zn against HRVs and 
the questionable success of clinical trial outcomes, over-the-counter therapeutics advertised to 
ameliorate the symptoms of the common cold suffer have a near ubiquitous presence in 
pharmacies around the world. While many anecdotal reports claim that these products are 
effective, the lack of a scientifically-backed mechanism for their antiviral activity has prevented 
both their optimization and wider acceptance. While the immune system bolstering presence of 
Zn does not render these products harmless or useless, the potential efficacy of these products to 
specifically target HRVs cannot be improved upon without a deeper understanding of their 
precise inhibitory activity. Historically, investigations into this inhibitory mechanism were 
focused upon the intracellular stage of viral infection. In this body of work I took a new approach 
in trying to understand Zn-based inhibition of HRVs by formulating a hypothesis predicated 
upon extracellular-based Zn activity. After demonstrating that this hypothesis was valid, I sought 
to characterize this route of inhibition and understand the mechanism of Zn’s rhinovirus-specific 
inhibitory potential. After confirming and characterizing this extracellular-based inhibition of Zn, 
I developed experiments to methodically hone in on the mechanism of this antiviral activity. In 
addition, I examined the genome of Zn-resistant HRV1A to uncover the determinants of genetic 
susceptibility that these viruses lack, and in doing so, understand how Zn might be interacting 
with the HRV1A virion. Taken together, my experimentation demonstrates that Zn catalyzes the 
degradation of viral RNA, thereby abrogating the infectivity of the viral population. I also 
demonstrated that some Zn Ionophore complexes are capable of extracellular-based inhibition of 
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HRVs as well, though their involvement in RNA degradation-based inhibition is unclear. While 
my studies do not preclude the possibility that Zn may also work to inhibit HRVs on an 
intracellular level, it does demonstrate and describe a mechanism of extracellular Zn-mediated 
inhibition of HRVs that can be used to hone the efficacy of Zn-based products intended to work 
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